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INTRODUCTION 
Viruses are and will always be a part of every ecosystem, wildlife and human 
life. In the past, different viral outbreaks have left painful marks on humankind. 
Not surprisingly, countermeasures against different virus-caused epidemics also 
have a long history. It has been estimated that in 1000 AD, inoculations were 
already being used to prevent smallpox in China, Africa and Turkey. After 
some time, smallpox reached Europe and the Americas, where it caused a tre-
mendous number of deaths. The older method – variolation – was replaced by 
the use of a vaccine against smallpox in 1796 by Edward Jenner. In 1885, Louis 
Pasteur introduced the rabies vaccine. Both of these vaccines pre-dated the dis-
covery of viruses. In the 20th century, when actual viral pathogens were dis-
covered, more modern methods became available, and a number of different 
vaccines were developed. The use of vaccines has greatly reduced both the 
number of infections and virus-caused pathology. Compared to the vaccines, the 
use of antiviral compounds (i.e., chemical inhibitors of the viral infection cycle) 
has a much shorter history.  
Despite extensive research, some viruses and viral diseases still lack any 
good vaccine or treatment. Additionally, some viruses that currently have no 
importance or are efficiently controlled have the potential to become problems 
in the future. Viral features such as a high mutation rate, the ability to undergo 
recombination, diversity, the ability to escape immune systems and the com-
plexity of the viral lifecycle are only some of the obstacles that must be over-
come for antivirals and vaccines to be safe and efficient. Furthermore, vacci-
nation (where available) currently only helps to prevent new infections. In the 
case of chronic infections, it is equally important to develop effective and 
affordable cures for the disease in order to reduce mortality and improve the 
quality of life of people who are already infected. 
Hepatitis C virus (HCV) was discovered in 1989 (1), approximately 26 years 
ago, and yet there is no anti-HCV vaccine. Without an efficient vaccine, the 
options for combating HCV infection are limited to the use of antiviral drugs. In 
recent years, anti-HCV treatment achieved a real breakthrough. Nevertheless, 
HCV is still widespread and continues to produce disease. Different medi-
cations are needed to control HCV-induced pathology, spread and persistence. 
The first part of this dissertation is focused on the development of anti-HCV 
inhibitors using two different technological approaches.  
 Chikungunya virus (CHIKV) re-emerged in the past decade and is currently 
spreading around the world, affecting millions of people. This virus has gained 
the status of the causative agent of an acknowledged neglected tropical disease 
(2). The second part of this study is focused on the analysis of a laboratory-
developed attenuated CHIKV vaccine strain, including the characterization of 
its genetic stability, and work that aims to reveal the importance of the in-
troduced changes for the viral lifecycle.  
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1. REVIEW OF THE LITERATURE  
1.1. New emerging viruses, outbreaks and epidemics 
Viral outbreaks occur in different parts of the world every year. These outbreaks 
are frequently large enough to be called epidemics. Some of these outbreaks are 
predictable like influenza virus A; such epidemics occur every year, although 
the viral strains that cause these epidemics are generally different. Other viral 
outbreaks can be completely unexpected, such as the emergence of SARS-CoV 
in Asia in 2003 (3, 4) and the MERS-CoV outbreak that started in Saudi-Arabia 
in 2012 and has reached remote countries, such as South Korea and Thailand (5, 
6). Filoviruses in Africa cause sporadic outbreaks, although a recent Ebola out-
break in West Africa demonstrated that under the right circumstances (for 
virus), even viruses that lack an efficient means of transmission can spread 
rapidly and get out of control (7). Increased travel simplifies the spread of 
viruses/diseases between continents. The international economy and transport of 
goods has resulted in the spread of viral transmission vectors, such as mos-
quitoes. Human pressure on the natural habitats of viruses has increased the 
possibility of human contact with potentially pathogenic viruses.  
The viruses that have benefited most from these factors appear to have one 
thing in common: an RNA genome. In this group of viruses, the intrinsic abili-
ties of the viruses to mutate and adapt rapidly are especially prominent. Often, 
first-line measures, such as the monitoring of pathogens and their outbreaks, are 
not efficient, and the precautions that are taken to minimize the spread of poten-
tial pathogens fail. Therefore, there is a growing need for the development of 
efficient antiviral strategies. Correspondingly, a number of basic questions must 
be addressed in order to succeed in the development of vaccines or antivirals. 
Current technologies are fast and efficient; a potent antiviral drug (or vaccine) 
can be produced rapidly, but only when we have a precise design for the anti-
viral (or vaccine). Otherwise, the powerful technology may turn out to be a fast 
track to failure. Thus, it is important to study different strategies of vaccine 
development (or different technological platforms for the development of anti-
virals), even if the developed compounds/vaccine candidates have a relatively 
small chance of actually being used against viral infections. 
 
 
1.2. Current vaccines against viruses 
All vaccines act through the immune system, and (with the exception of passive 
vaccination), they induce efficient and long-lasting (ideally lifelong) protection 
against pathogens. The immune system has been shaped to be efficient against 
pathogens, and a successful vaccine must safely mimic a pathogen. There are 
multiple ways to achieve this goal. Given the complexity of immune system/ 
pathogen interactions, different approaches have different benefits and dis-
advantages. 
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1.2.1. Inactivated (killed) vaccines 
The principle of inactivated vaccines is based on treating the pathogen in the 
way that it becomes unable to cause infection but maintains the ability to acti-
vate the immune system. This type of vaccine is known for its safety features. 
“Killed” pathogens can no longer replicate; therefore, no mutations or re-acti-
vation of the virus could occur. Other positive features of this type of vaccine 
include their inability to be transmitted. In addition to these biological proper-
ties, inactivated vaccines are easier to handle. They are not as demanding in 
terms of storage conditions (at least in comparison to live attenuated vaccines), 
making their transportation and distribution much more convenient. However, 
like all other types of vaccines, they have some disadvantages. Compared to 
live attenuated vaccines, inactivated vaccines stimulate a weaker immune 
response and sometimes provide poorly sustained protection. Therefore, mul-
tiple doses and/or boosts of inactivated vaccines are needed to achieve proper 
immunity. For instance, the vaccine against the tick-borne encephalitis virus 
(TBEV) requires three injections and subsequent booster vaccinations every 
three to five years to maintain protective immunity (8). 
There are a number of strategies for inactivating pathogens for vaccine 
development purposes: gamma irradiation (9–11), ultraviolet treatment (12), 
heat (13) or the use of different chemicals. Inactivating chemicals include acids 
(14), ethylenimine derivatives (15), psoralens (16) and hydrogen peroxide (17, 
18). Formaldehyde and β-propiolactone (BPL) are the main chemicals used in 
the production of licensed human vaccines. BPL inactivates the virus through 
interactions with viral nucleic acid (19); meanwhile, formaldehyde-mediated 
inactivation is based on crosslinking various amino acid residues in viral pro-
teins (20, 21). For enveloped viruses, inactivation with mild detergents is com-
monly used (22). 
Today, this type of vaccine is licensed (for human usage) against six viruses: 
poliovirus (PV) (23) hepatitis A virus (HAV), Japanese encephalitis virus 
(JEV), TBEV, rabies virus and influenza virus. There are also several vaccine 
candidates of this type in clinical development. The targeted viruses include 
Ross River virus (RRV) (24), CHIKV (25), respiratory syncytial virus (RSV) 
(26) and enterovirus 71 (27). Inactivated dengue virus vaccine research has been 
put on hold due to the lack of an equally protective immune response against all 
four serotypes of the virus and the risks of waning immunity (28). There are 
also inactivated vaccines for VEEV and EEEV that are licensed for horses but 
not for humans (29).  
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1.2.2. Subunit vaccines 
In the case of subunit vaccines, only part of the viral genetic information is used 
to produce materials required to induce a protective immune response. Such 
vaccines are generally based on virus proteins that are generated using recombi-
nant DNA and protein expression/purification technologies. Subunit vaccines 
have numerous advantages over traditional inactivated vaccines. These vaccines 
do not contain a pathogen; therefore, this approach lacks all concerns related to 
pathogen inactivation and the effects of such treatments on the antigenic proper-
ties of viral proteins. The disadvantages of this approach include the problem of 
insufficient immune activation and protection against a pathogen. In general, 
monomeric viral proteins are poor antigens. Therefore, most subunit vaccines 
represent artificial particles composed of viral proteins (virus-like particles or 
VLPs). Thus, the possibility of obtaining a good subunit vaccine also depends 
on the ability of viral proteins to form VLPs. 
The first subunit vaccine was the vaccine against hepatitis B virus (HBV), 
which contains the viral surface antigen HBsAg produced in yeast. This antigen 
forms distinct particles that are very similar to the so-called 20 nm spheres pro-
duced in HBV-infected humans (30). This vaccine was licensed in 1986. Cur-
rently, there are some positive advances in HIV subunit vaccine development 
(31, 32), although the protective immunity generated by such vaccines is short-
lived. Much work has been conducted towards the development of subunit vac-
cines for dengue virus; to date, promising results have been obtained using non-
human primates (33). The subunit vaccines against Ebola virus have reached 
clinical trials (34). In addition, great success has been achieved in the develop-
ment of subunit vaccines against oncogenic types of human papillomaviruses 
(35). These vaccines are very immunogenic and generate protective immune 
responses that do not fade over a period of nearly 10 years (36, 37) and, in all 
likelihood, will last much longer (currently, such data are not available, as these 
new vaccines were approved in 2006/2007).  
 
 
1.2.3. Attenuated (live) vaccines and recombinant vaccines 
Attenuated vaccines are viruses that are still able to replicate and cause infection 
but do not cause disease. Such vaccines are very effective in activating both 
humoral and cellular immune responses and typically produce long-lasting 
protection following a single-dose immunization. The negative sides of live 
vaccines are the risk of reversion of the attenuated virus back to a pathogenic 
version and the risk of transmission. 
The first so-called attenuated vaccine was the smallpox vaccine developed 
by Jenner in 1796. The actual virus that was used as the vaccine was not an 
attenuated strain of variola virus but a related cowpox virus. The true attenua-
tion of pathogenic viruses can be achieved using different approaches. Histori-
cally, pathogenic viral strains were passaged multiple times under unfavourable 
4
14 
conditions – in different hosts and/or at sub-optimal temperatures – until a non-
pathogenic phenotype was obtained. For example, the attenuated polio vaccine 
was developed by Sabin after years-long passaging of the virus in different 
hosts after inoculation via different routes. This approach resulted in the 
development of a non-virulent PV strain that was licensed as a vaccine in 1960. 
A number of other attenuated vaccines were obtained using similar approaches, 
including the yellow fever virus vaccine (38), the measles and mumps vaccines 
(39, 40) and the rotavirus vaccine (41). 
As we know now, under these conditions, certain attenuating mutations are 
generated in viral genomes. Current recombinant DNA technology and syn-
thetic biology allow the direct introduction of all types of modifications into 
viral genomes. This approach is much faster and allows for the rapid analysis of 
modified viruses for pathogenicity, immune activation and stability in cell cul-
ture-based systems, in different animal models and ultimately in clinical trials. 
Intensive research has been carried out with the aim of developing attenuated 
vaccines for dengue virus, CHIKV and RSV using this modern approach. 
In the case of recombinant (chimeric) vaccines, the antigen(s) of a pathogen 
of interest are inserted into a heterologous vector, which is usually derived from 
an approved vaccine strain of a different virus. This strategy is commonly used 
for modern veterinary vaccines, for which it has been found to be very efficient. 
In contrast, this approach is not yet widely used for the development of human 
vaccines. The only recombinant vaccine is the vaccine against JEV 
(ChimeriVax-JE), which represents a recombinant between the yellow fever 
vaccine (vector part) and the JEV (part encoding for envelope proteins) (42). 
The anti-rotavirus vaccine RotaTeq, which contains five human-bovine rota-
virus hybrids, is also a chimeric virus-based vaccine. However, this vaccine is 
not a product of true recombination; instead, it was obtained via the re-assort-
ment of genome segments from different viruses (43). The modern chimeric 
vaccine development approach has also been used to generate vaccine candi-
dates against CHIKV (see 1.5.5.) 
 
 
1.2.4. DNA vaccines (gene vaccines) 
The production of naked DNA is much less complex and less expensive than 
the production of VLPs or proteins. Thus, the principle of this vaccine tech-
nology is introducing recombinant DNA that encodes the desired epitope(s), full 
proteins or even the full attenuated virus genome straight into the tissue. The 
peptide or protein is expressed in situ and should, at least in theory, produce an 
immune response against the desired pathogen. Similar to subunit vaccines, the 
pathogen itself is not present, and the safety concerns are primarily related to 
the possibility of unwanted integration of vaccine DNA into the human genome. 
The first report of the effective introduction of plasmid DNA and subsequent 
antigen expression in an organism dates back to 1990 (44); as the technology 
appeared to be rather straightforward, many examples followed. In 1993, Ulmer 
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demonstrated that the injection of mice with naked DNA encoding an influenza 
virus protein can protect animals against challenge with wild-type (wt) influ-
enza virus (45). The recent development of molecular engineering, including 
gene synthesis, provides practically unlimited possibilities for the construction 
of different DNA molecules. Together with an improved understanding of 
innate immune responses, this technology has boosted interest in the develop-
ment of DNA vaccines.  
Since 2005, at least three DNA vaccines have been licensed for veterinary 
use: one vaccine targeting West Nile virus in horses (46), another targeting 
haematopoietic necrosis virus in salmon and a third targeting canine malignant 
melanoma (47). Nevertheless, the progress of development of human DNA vac-
cines has been slow, partly because of delivery issues and differences in the 
innate immune response between humans and animal models and, most impor-
tantly, because of much longer trial periods and enhanced safety concerns. As a 
result, there is not yet a licensed DNA vaccine for human use, although multiple 
DNA vaccine candidates have reached clinical trials (48–50). 
 
 
1.3. Antiviral drugs – principles and examples  
of different approaches 
As mentioned above, infections caused by many medically important viruses, 
including HIV-1 and HCV, cannot currently be prevented by vaccination. 
Similarly, the currently available vaccines cannot eliminate established infec-
tions. Therefore, treatments that can inhibit (or prevent) virus-induced patho-
genesis, limit virus spread and ideally eliminate the virus from infected 
organisms are needed.  
Not long ago, only different natural substances were used to treat diseases. 
Some of these natural medicines have indeed been proven to possess antiviral 
properties. However, the effects of these substances are rarely virus-specific, 
and their mechanisms of action often remain unknown. Nevertheless, the exis-
tence of such medicines has provided inspiration for the development of syn-
thetic antiviral drugs. Most of these substances directly target viral components 
(proteins or genomes); hence, these substances are called directly acting anti-
virals (DAA). Such substances (or, more commonly, their parental compounds, 
which are called “hits”) are typically obtained by screening large libraries of 
chemical compounds. Alternatively, the structures of potential hit compounds 
can be designed rationally by taking into account the known structures of viral 
macromolecules (drug targets) and multiple additional factors. Finally, instead 
of targeting the virus, antiviral compounds can target host factors that are essen-
tial for virus replication (host targeting antivirals, HTA). Antiviral compounds 
can target different steps of the viral lifecycle, including entry, replication, pro-
tein synthesis, maturation or the release of new viral particles. Currently, 
approximately 50 antivirals are licensed against major viral pathogens; approxi-
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mately half of these antivirals are against HIV-1. However, the number of sub-
stances with known antiviral effects is much larger. Thus, it is impossible to 
cover all of these substances in a single review. Therefore, only a brief descrip-
tion of nucleoside/nucleotide analogues and some non-nucleoside inhibitors is 
provided as an example. Antisense oligonucleotide-based drugs and drug candi-
dates are reviewed more extensively. Drugs that inhibit HCV are reviewed in 
chapters 1.4.5 and 1.4.6, as these drugs are most relevant to the topic of the cur-
rent thesis. 
 
 
1.3.1. Nucleoside/nucleotide analogues  
Nucleoside/nucleotide analogues mimic substrates of viral polymerases and 
generally act as terminators of DNA or RNA synthesis, abolishing genome 
replication (51). Such inhibitors tend to be rather specific (effective against one 
virus or a narrow group of viruses) and have been developed and licensed for 
use against herpesviruses (acyclovir) (52, 53), HIV-1 (AZT) (54, 55), HBV 
(telbivudine) (56) and now also against HCV (sofosbuvir) (57).  
Some other nucleoside inhibitors (for example, ribavirin and favipiravir) 
have a broad antiviral spectrum. Ribavirin is a synthetic guanosine analogue 
and is used in the clinical treatment of HCV, RSV and influenza virus infections 
and also for the treatment of infections caused by other (often rare and/or 
lacking specific inhibitors) viruses, such as Lassa virus and CHIKV. Depending 
on the targeted virus, ribavirin may be used with or without polyethylene 
glycol-conjugated interferon-alpha (pegIFN-α) and/or DAAs (58, 59). Ribavirin 
has other activities in addition to being a substrate for viral polymerase. For 
example it depletes the cellular pool of guanosine nucleotides, thus affecting 
viral replication/transcription (60, 61). Favipiravir is licensed (in some coun-
tries) for the treatment of influenza but has also been shown to inhibit several 
other viruses, including hantaviruses, Ebola virus and CHIKV (62–64). 
 
 
1.3.2. Non-nucleotide inhibitors  
Non-nucleotide inhibitors are extremely diverse in terms of structure, function 
and mode of action. The structure of such inhibitors may vary from small mole-
cules to proteins and the functionality may vary form very specific to very 
general inhibitors. Some of these compounds block viral enzymatic activities by 
acting as analogues of substrates or as allosteric inhibitors. Other compounds 
block virion internalization and unpacking, inhibit the release of new generation 
of particles or target host factors that are critical for the viral life cycle. Many of 
these compounds, such as allosteric inhibitors or substrate analogues, have high 
activity and narrow specificity. In these cases, the use of compounds with dif-
ferent mechanisms of action is needed for the efficient treatment of viruses that 
are capable of developing resistance against specific inhibitors.  
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Some non-nucleoside inhibitors are active against a broad spectrum of 
viruses. For example, chloroquine, which is an anti-malaria drug, has broad 
antiviral activity and acts by disrupting virus entry. In in vitro studies, chloro-
quine inhibited HIV-1, SARS-CoV, alphaviruses, influenza A virus and Ebola 
virus; however, in in vivo studies, chloroquine has generally failed to demon-
strate its effectiveness (65–69). Different immunomodulators, such as IFN-α, 
retinoic acid-inducible gene 1 (RIG-I) agonists and poly(I:C), act by boosting 
the immune system. Type I IFNs represent the first line of natural defence 
against virus infection and are therefore active against many viruses. IFNs acti-
vate the production of other cytokines and antiviral proteins and also activate 
cells of the immune system. Currently, IFN-α (typically in the form of pegIFN-
α) is used for the treatment of chronic HCV and HBV infections (70). As a key 
part of innate immunity, IFN-α is also responsible for the development of mul-
tiple side effects. 
 
 
1.3.3. Antisense oligonucleotides and antiviral siRNA 
Antisense oligonucleotides (ASOs), which are used as inhibitors of viral infec-
tion, are DNA, RNA or DNA/RNA mixomer (and different modified versions 
of these) molecules that are typically 18-25 nucleotides in length. These 
oligonucleotides are primarily designed to target viral mRNAs (in the case of 
positive-strand RNA viruses, these compounds target viral genomes that func-
tion as mRNAs). Depending on their composition, ASOs may activate different 
downstream pathways that lead to targeted RNA degradation and/or cause the 
steric blockade of mRNA translation (for viral genomes, also replication) by 
binding to their target sites in RNA molecules and interfering with the cellular 
translation machinery (71) and/or viral replicase.  
ASOs are designed to bind to specific positions in viral mRNAs (or 
genomes), mRNAs that encode proviral host factors or cellular micro RNA 
(miRNA). This feature ensures the specificity of the effect but also represents 
an intrinsic weakness of ASOs. To be highly effective, the sequence of an ASO 
must have a perfect or nearly perfect match with its target sequence. For host 
targets that have conserved sequences, this requirement is relatively easy to 
achieve. In contrast, RNA viruses are genetically very variable; such viruses 
often have different genotypes (GT) and each GT exists in the form of quasi-
species. Hence, such virus populations have some pre-existing resistance to 
ASOs and can acquire additional mutations very rapidly. When resistant vari-
ants of genomes become prominent, the antiviral efficiency of ASOs can be lost 
or severely diminished. 
The simplest ASOs are DNA oligonucleotides. Such ASOs bind to the target 
RNA and form DNA:RNA heteroduplexes. Such duplexes cause translational 
arrest but can also be recognized and then degraded by cellular RNase H1 (71). 
Hence, ASO-mediated inhibition depends on the functions of the target site. To 
cause translational arrest, the target of an ASO must overlap with sequences that 
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are essential for the initiation of translation. Furthermore, the probability of 
ASO binding greatly depends on the secondary structure of the target RNA 
(72). The actual structures of viral RNAs are complex, especially in cells, where 
they are dynamic and difficult to analyse. When designing an ASO, it is impor-
tant to take into account these structures; regions that are actually accessible 
(and not hidden by secondary structures) should be targeted (71, 73). Different 
computer programs are designed to predict RNA secondary structures, but these 
predictions are often not supported by experimental data. The more accurate 
methods, such as SHAPE (selective 2'-hydroxyl acylation analysed by primer 
extension), can provide better predictions (74), but such approaches are also 
more time- and resource-demanding. In addition, all viral RNAs form 
RNA:protein complexes, which may hide potential ASO target sites. The 
effect(s) of such complex formation on the secondary structure of RNA is hard 
to predict. Thus, the design of efficient ASOs is not as simple as it may look. 
Finally, even if the issues with target site selection are solved, DNA ASOs 
remain nearly useless due to poor cellular uptake, low stability against enzy-
matic degradation, unwanted side effects and low binding efficiency. Many of 
these disadvantages of DNA ASOs can be overcome or alleviated by including 
different modifications in the ASO design.  
To date, numerous modifications that enhance the inhibitory properties of 
ASOs have been described. Phosphorothioate oligonucleotides (PTOs), where a 
non-bridging oxygen on the phosphate backbone is replaced by a sulfur atom, 
are commonly used. This modification renders the internucleotide linkage resis-
tant to nuclease degradation. The downside of this modification is a reduced 
melting temperature (Tm) and reduced stability of the ASO:RNA duplex (75). 
To further enhance ASO stability and improve binding properties, other modi-
fications, such as 2′-O-Methyl (2′-OMe) or 2’-O-methoxyethyl RNAs (76), 
peptide nucleic acids (PNA) (77), tricyclo-DNA (78), boranophosphate- (79), 
oxepane- (80), cyclohexene- (81), fluoro-arabino (FANA)-modified ASOs (82), 
N3’,P5’ –phosphoramidates (83), morpholinos (84), and/or 2’-O-methyl locked 
nucleic acids (LNA) (85), have been developed and used. 
Although most of these modifications increase the binding affinity of ASOs 
for the target RNA and enhance the stability of the formed duplex, they often 
cause problems. Excessively strong binding to the target can result in increased 
binding to non-targeted RNAs; effects that result from such interactions are 
termed off-target effects. In addition, RNase H-mediated degradation requires a 
duplex containing 6 or more DNA:RNA base pairs that are not interrupted by 
LNA, PNA, morpholino or 2’OMe modifications (71). Thus, when including 
different modifications in ASOs, it is important to know the mechanism(s) by 
which these modifications contribute to improved inhibitory effects and poten-
tial disadvantages associated with these modifications. The questions of where, 
how many and which type of modifications should be included are clearly cru-
cial for efficient ASO design. As a result, the current situation with ASOs is 
quite similar to the situation with other types of antiviral compounds. There are 
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many reports of the successful application of ASOs against different viruses in 
cell culture. The viruses that have been targeted include HCV (86) and CHIKV 
(87). In some cases, antiviral effects have also been observed in in vivo models 
(87, 88). However, only a few ASOs that are designed to target viruses (in-
cluding influenza virus, Ebola virus and HCV) have reached clinical trials (89). 
To date, the only ASO-based antiviral drug that is licensed for clinical use is the 
intraocular drug fomivirsen, which was used for the treatment of human 
cytomegalovirus (HCMV)-caused retinitis (90). This drug was approved in 
1998 and withdrawn a few years later due to poor demand. 
Small interfering RNAs (siRNA) are dsRNA molecules that induce RNA 
interference (RNAi), which leads to the degradation of the targeted RNA. 
siRNAs have many similarities to ASOs (including a similar size – typically 21 
nucleotides), but unlike ASOs, siRNAs are components of natural regulatory 
systems, and even when introduced into cells artificially, siRNAs still act via 
complicated pre-existing molecular machinery. Briefly, one strand (called the 
guide strand) of the siRNA molecule is loaded into the RNA-induced silencing 
complex (RISC) and is bound to the complement target RNA, leading to its 
degradation (91). This pathway is used extensively in molecular biology studies 
as an easy option for down-regulating specific genes or inhibiting viruses in in 
vitro systems. In in vivo models and especially in potential therapeutic appli-
cations, many unsolved problems, such as inefficient delivery, poor target 
organ/tissue specificity, low stability of the compound and off-target effects, 
limit the use of siRNAs as antivirals (reviewed in (92)). 
   
 
1.4. Hepatitis C virus (family Flaviviridae) 
Hepatitis C virus (HCV) belongs to the family Flaviviridae and is currently the 
only recognized member of the genus Hepacivirus. This status will certainly 
change in the future, as similar viruses were recently discovered in horses, dogs, 
bats and rodents (93–97). It is estimated that approximately 3% of the world 
population is chronically infected with HCV. Although this infection is often 
asymptomatic, chronic HCV infection may lead to severe liver diseases, such as 
fibrosis, cirrhosis and finally hepatocellular carcinoma (HCC). HCV is associated 
with significant mortality resulting from these liver-associated diseases but has 
also been linked to several metabolic, cardiovascular, neurological and im-
munological disorders (98, 99). Due to its medical importance, HCV is currently 
the third most studied virus in the world (after HIV and influenza viruses).  
 
 
1.4.1. HCV genotypes, distribution and HCV-induced diseases  
HCV has very high genetic diversity. Seven different HCV GTs are currently 
recognized, with additional grouping into subtypes. Strictly speaking, the classi-
fication is justified only from the medical point of view since different HCV 
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GTs cause similar clinical diseases. From the perspective of virus systematics, 
this classification is misleading. The similarity of nucleic acid sequences 
between different HCV GTs is as low as 65%. In the case of almost any other 
group of viruses, the current HCV GTs would be considered as different virus 
species (rather than variants of a single virus). In addition, different HCV GTs 
also exhibit different levels of responsiveness to antiviral treatment. 
HCV prevalence and GT distribution vary around the world (Fig. 1). 
Globally, the most common and prevalent GT is GT1 (46% of all HCV cases), 
followed by GT3 (30%), GT2 and GT4. GT1 is distributed most widely and is 
prominent in Europe, Australia, South America and North America. GT3 is 
distributed mainly in Asia but is also rather common in Australia and South 
America. In Africa and the Middle East, the most prominent GT is GT4 (100–
102). 
 
 
 
Figure 1. Distribution and prevalence of HCV GTs. The map is derived from Messina 
et al. 2015 “Global distribution and prevalence of hepatitis C virus genotypes.” Hepa-
tology, 61: 77–87. doi: 10.1002/hep.27259 (102). 
 
 
HCV is a blood-transmitted virus. Virus-containing blood is highly infectious; 
therefore, transmission via contaminated blood is very efficient. Primary HCV 
infection is usually asymptomatic or is associated with very mild symptoms and 
is therefore typically not recognized and diagnosed. Only 15–45% of infected 
patients clear the virus, while in 55–85% of patients, primary infections are 
followed by chronic HCV infection (103, 104). The likelihood of clearing the 
primary infection depends both on the HCV GT (being lowest in the case of 
GT1 (103)) and on host factors. The first and the most prominent determinant 
that is known to affect the probability of clearing HCV infection (and also the 
efficiency of anti-HCV treatment) is the single nucleotide polymorphism 
rs12979860, which is located 3 kb upstream of the IL28B (interferon λ3) gene 
(105–107).  
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HCV has been shown to infect monocytes (108), lymphocytes (109) and 
some other cell types (110); however, the main target of the virus is the liver 
and hepatocytes (111). Chronic HCV infection in the liver leads to fibrosis 
(112) and cirrhosis and can result in HCC. It is estimated that more than 
350,000 people worldwide die from HCV-related liver diseases each year, and 
HCV-induced cirrhosis is the major reason for liver transplantation in Western 
countries. The mechanisms by which HCV induces these diseases are not obvi-
ous, as HCV infection itself is not cytotoxic. However, chronic HCV infection 
is associated with an inflammatory response in the liver. HCV infection and 
disease progression can be hidden for decades until the liver structure is seri-
ously damaged and the disease culminates with cirrhosis. The other liver 
disease that is associated with HCV infection is steatosis (reviewed in (113)). 
Steatosis is often correlated with the progression of fibrosis and the devel-
opment of HCC. The molecular basis of HCV-induced steatosis is in the tight 
connection of HCV infection with lipid metabolism. Thus, HCV infection leads 
to changes in cellular metabolism that promote the accumulation of lipid drop-
lets (LD). The triglycerides and cholesterol esters that are found in the HCV-
infected liver differ from those of obese patients, suggesting the existence of a 
different course of steatosis (114). HCV infection is also linked to insulin resis-
tance and oxidative stress. Moreover, due to the ability of HCV to interfere with 
different immune and metabolic pathways, HCV infection is also associated 
with a number of extrahepatic manifestations, including neuropsychiatric symp-
toms, cardiovascular diseases, fatigue and autoimmune syndromes (99). 
 
 
1.4.2. HCV virion and genome 
The structural characterization of infectious HCV particles has faced many 
obstacles. Different studies have indicated the diversity of HCV particles circu-
lating in human serum. These particles can vary in size (40–100 nm) and den-
sity (1.03 to 1.25 g/ml), and the glycoprotein spikes are often barely distin-
guishable. The analysis of cell culture-produced HCV virions (ccHCV) also has 
problems, as the morphologically uniform particles have a different density than 
the infectious particles (115). Similarly, the composition of HCV particles 
depends on the source from which the particles were obtained. Nevertheless, the 
basic structure of the HCV virion is now reasonably well known (Fig. 2A). The 
HCV virion contains an RNA genome that is packed into a shell made of capsid 
protein. This nucleocapsid is surrounded by the endoplasmic reticulum (ER)-
derived envelope that contains HCV E1/E2 glycoprotein heterodimers and 
cellular ApoE proteins. Structural analyses carried out using EM have shown 
the presence of a non-continuous lipid bilayer that might be caused by the 
embedding of lipoproteins into HCV particles (115, 116).  
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Figure 2. A. Schematic presentation of an HCV virion. B. HCV lifecycle: 1. Receptor-
mediated virion binding 2. Virion internalization and nucleocapsid release into the cyto-
plasm 3. Genome translation 4. Replication complex formation on ER-derived mem-
branes 5. Replication of the viral genome and nucleocapsid formation 6. Virion matu-
ration at the Golgi complex and exit by exocytosis C. Schematic presentation of the 
HCV genome and the virus-encoded polyprotein. Anti-HCV DAAs (clinically approved 
compounds and compounds in late stages of clinical trials) are listed below their targets. 
 
 
The HCV genome is positive-strand RNA approximately 9.6 kb in length. The 
genome contains one long major open reading frame (ORF) (Fig. 2C) and at 
least one overlapping shorter ORF. The HCV genome lacks a 5’ cap and 3’ 
poly(A) structures, but its 5’ and 3’ untranslated regions (UTRs) are highly 
structured and contain crucial elements that are required for genome translation 
and replication:  
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- The 5’ UTR contains sites for binding the cellular miRNA mir-122; these 
sites are essential for HCV genome translation and replication. As mir-122 is 
expressed primarily in the liver, the presence of such sites contributes to the 
hepatotropism of HCV (117). Another essential structure that is located in 
the 5’ UTR is an internal ribosome entry site (IRES) that has two well-
described functions. This site acts as an initiator of translation and partici-
pates in the regulation of negative-strand RNA synthesis (118, 119).  
- The 3’ UTR consists of a variable domain, a poly(U) tail and a conserved X 
tail that enhance genome translation and are crucial for the synthesis of 
negative-strand RNA (120–124).  
 
IRES-mediated translation results in the synthesis of a large (~3000 amino acid 
(aa) residues) precursor polyprotein (Fig. 2C). During its synthesis, the N-termi-
nal part of this polyprotein interacts with ER membranes. This polyprotein is 
co- and post-transnationally processed by cellular and viral proteases into 10 
mature proteins. Of these proteins, C (capsid protein), E1 and E2 are structural 
proteins, and the remaining proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and 
NS5B) are non-structural proteins (Fig. 2C) (123–125).  
 
 
1.4.3. HCV structural and non-structural proteins  
Together with the RNA genome, Capsid protein (C, also known as Core 
protein) forms the nucleocapsid of the HCV virion. Capsid protein is first 
released from the polyprotein in its immature form (191 aa) and is further 
processed by a signal peptidase to generate the mature protein of 177 aa (126). 
The N-terminal part of the protein contains an RNA binding domain and is 
important for the formation of homo-oligomers. The C-terminal part of the pro-
tein mediates the association with LD and has also been shown to induce LD 
formation (127). The interaction of the capsid protein with NS5A and LD is 
critical for the assembly of HCV particles (128, 129). 
E1 and E2 are the envelope glycoproteins that are essential for virion attach-
ment, internalization, membrane fusion and the maturation of new virions. E1 
and E2 are highly glycosylated and occur in the form of heterodimers. The E1 
and E2 heterodimer is stabilized by disulphide bonds and is arranged to the 
membranes of budding virions (130). E2 is also the major HCV antigen and 
facilitates the receptor-binding step in virus attachment to cells. The structure of 
the E2 core domain was recently resolved by two research teams (131, 132). 
Despite the fact that E2 was also considered to mediate membrane fusion both 
of these studies failed to reveal the structural hallmarks of the fusion protein 
(132, 133). Similarly, the partial 3D structure of the E1 protein (in the form of a 
homodimer) lacks folding characteristic of class II fusion proteins (134). It was 
only recently found that during virion assembly, E1/E2 heterodimers are 
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rearranged, and E1 trimers are formed. This re-arrangement is consistent with a 
possible role of E1 as an HCV fusion protein (135).  
P7 is a small transmembrane protein with both termini orientated to the ER 
lumen. P7 is essential for virion assembly and release both in vitro and in vivo 
(136, 137), probably because it is needed for the final steps of capsid assembly 
and envelopment (138). P7 is a viroporin and forms hexamers or heptamers 
with cation-channel activities. It has been hypothesized that these ion channels 
prevent acidification in intracellular compartments that normally have acidic 
environments. This loss of acidification is required for productive HCV infec-
tion, possibly by protecting nascent virus particles during the maturation 
process (139).  
NS2 is a membrane–associated protein with two distinct functions. First, the 
highly conserved (between different HCV GTs) C-terminal part of NS2 (aa 
residues 94–217) contains a cysteine protease domain (140). The protease 
activity of NS2 is enhanced by the N-terminal part of NS3 and is required for 
the processing of the site between NS2 and NS3. This cleavage is essential for 
obtaining free NS3, which is in turn required for HCV genome replication. 
Interestingly, NS2 itself is not required for HCV RNA replication (141). 
Second, NS2 plays a central role in virion assembly. It is hypothesized that for 
this function, the membrane binding domain of NS2 and complex protein-
protein interactions mediated by NS2 are required. However, the exact mecha-
nisms by which NS2 participates in infectious particle production are not yet 
known (142–146). 
NS3 is a large protein that consists of N-terminal protease and C-terminal 
NTPase/RNA helicase domains. These enzymatic activities have been shown to 
work independently of each other, although they are enhanced by the presence 
of both domains of NS3. 
The NTPase/RNA helicase domain is a very well-characterized member of 
helicase superfamily II. This domain is essential for viral RNA replication and 
probably acts by unwinding RNA secondary structures and dsRNA replication 
intermediates. NS3 does not discriminate between its natural substrate (RNA) 
and DNA and is also able to bind and very efficiently unwind DNA (147). Bio-
chemical assays of NS3 helicase activity have shown that the pH optimum for 
the enzyme is ~6.4. Relatively low pH values likely promote more efficient 
conformational changes of NS3, resulting in higher enzymatic efficiency (148). 
NS3 is also a serine protease; the protease fold covers the N-terminal third of 
the protein. The catalytic triad consists of the His57, Asp81, and Ser139 resi-
dues. For optimal protease activity, the NS4A protein is needed as a cofactor. 
Together, these proteins form the fully active NS3/4A serine protease that per-
formes the processing of the non-structural part of the HCV polyprotein (149–
153). The 3D structure of NS3/4A reveals that two β-barrel subdomains of NS3 
and the central portion of NS4A form a chymotrypsin-like fold, which is sta-
bilized by Zn2+ ions. The N-terminal part of NS4A forms a transmembrane α-
helix that mediates membrane binding of NS3/4A, while the C-terminal domain 
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of NS4A interacts with other replicase components. It has been shown that the 
protease activity of NS3/4A depends on the positioning of its active site with 
respect to membranes. The conformational flexibility of the enzyme is achieved 
via a linker segment located between the helicase and protease domains of NS3 
(154).  
The substrate binding site of the NS3/4A protease can accommodate pep-
tides with a length of 6 aa, but the most efficient cleavage is obtained for longer, 
10 aa substrates. The consensus sequence of the substrate is D/E-X-X-X-X-
C/T↓S/A-X-X-X (155, 156). This consensus sequence is not only present in the 
viral polyprotein but can also be found in a variety of host proteins. One of the 
best known host targets of the NS3/4A protease is the adaptor protein MAVS 
(156). NS3/4A cleaves this protein and thus interferes with innate immune 
responses mediated by the RIG-I/MDA-5 pathway. However, MAVS is not the 
only host protein involved in pathogen recognition that is cleaved by NS3/4A. 
The enzyme is also known to cleave TRIF, which is an adaptor for the TLR3 
(155), DDB1 (157) and GPx8 (158) proteins. 
NS4B has four transmembrane segments and forms three different domains 
(159). NS4B harbours NTPase activity and has been shown to bind RNA (160, 
161). This protein induces the formation of a membranous web, which is critical 
for the assembly of HCV replication complexes (162). The N-terminal domain 
of NS4B mediates protein-protein interactions, and its topology is dependent on 
other replicase proteins (163). The C-terminal part of NS4B contains two α-
helixes and is palmitoylated (164). This domain is also involved in protein-
protein interactions and is important for the oligomerization of NS4B molecules 
(165). NS4B oligomerization appears to be the key determinant for the induc-
tion of vesicle formation (166). 
NS5A is a multifunctional protein that is anchored to membranes by its N-
terminal part. NS5A contains three domains (D1, D2, and D3) that are separated 
by low complexity sequences (167). The D1 domain forms dimers and can 
facilitate RNA binding (168); this domain also can bind Zn2+ ions via cysteine 
residues (167). The D1 domain is also involved in binding to LDs, and together 
with the D2 domain, this domain is important in RNA replication (169). The D2 
and D3 domains are thought to facilitate interactions with host proteins. To 
date, NS5A has been shown to interact with more than 130 host proteins. It has 
been hypothesized that this large number of interactions originates from the 
ability of NS5A to be present in different states of phosphorylation and from the 
abilities of D2 and D3 to acquire different conformations. Indeed, the D2 and 
D3 domains contain serine residues that can be phosphorylated; both basally 
and hyper-phosphorylated forms of NS5A can be found in infected cells (170, 
171). The D3 domain also interacts with the capsid protein, indicating its role in 
virion formation (129).  
NS5B is an RNA-dependent RNA polymerase (RdRp). The large catalytic 
domain is located in its N-terminal part (530 aa) and is followed by a linker 
sequence and a C-terminal peptide (21 aa), which serves as a membrane anchor. 
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The 3D-structure of the catalytic domain of NS5B shows a classical “right 
hand” organization, with finger, thumb and palm domains (172). The finger and 
thumb domains provide contacts with RNA, and the palm region contains the 
catalytic site. For de novo and primer-dependent synthesis, the RdRp needs 
divalent metals as cofactors. The primary conformation of NS5B appears to be 
the “closed hand,” in which the template binding groove fits only ssRNA and 
uses nucleotide for priming (173). This conformation is used in the initiation of 
the synthesis of HCV negative-strand RNA. The subsequent elongation step 
requires the open conformation of NS5B, as the groove must accommodate the 
primer-template RNA complex (174, 175). NS5B also appears to have a spe-
cific role in replication complex assembly that is distinct from its RdRp activity 
(176). 
 
 
1.4.4. Hepatitis C virus infection cycle 
Hepatocytes are the main targets of HCV. The infection starts with the attach-
ment of viral particles to specific cell receptors, primarily via E2 (Fig. 2B). The 
entry of HCV is a very complex process and involves interactions with many 
different host factors. Binding is initiated by attachment to glycosaminoglycans 
and/or lipoprotein receptors (177, 178). This attachment is followed by coordi-
nated interactions of HCV particles with the scavenger receptor class B type I 
(179) and a major receptor of high-density lipoprotein – CD81 tetraspanin 
(180). These interactions trigger subsequent interactions of HCV with the tight 
junction proteins claudin-1 (181) and occludin (182). This set of particle-recep-
tor interactions ultimately leads to the uptake and cellular internalization of 
HCV through clathrin-dependent endocytosis. The precise mechanism of mem-
brane fusion and particle uncoating remains to be discovered.  
After fusion, the RNA genome is released into the cytoplasm of the cells and 
translated into a viral polyprotein in a cap-independent manner. Translation is 
mediated by an IRES structure located in the 5’ UTR of the RNA genome (183, 
184). In addition to the basic translation machinery, additional cellular factors 
are known to stimulate IRES activity. During synthesis, the polyprotein binds to 
the ER membrane (Fig. 2B) and is co- and post-translationally cleaved by viral 
(NS2/3 and NS3/4A) and host proteases into mature proteins (185).  
Viral non-structural proteins are needed for the initiation of HCV RNA repli-
cation (149, 151, 152, 185), and their accumulation initiates the formation of 
multi-membrane vesicles. The HCV replication complexes are most likely ER-
derived “double-membrane vesicles” (186). The morphology and exact compo-
sition of these complexes are poorly understood. The newly formed replication 
complex uses the viral genome as a template for negative-strand RNA syn-
thesis. As with other positive-strand RNA viruses of eukaryotes, the negative-
strand RNA likely forms a duplex with the complementary positive strand. For 
the synthesis of new genomes, the viral RdRp uses the negative-strand RNA of 
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the duplex as a template. Newly synthesized positive-strand RNAs either re-
enter the replication cycle or are directed to viral particle formation (187, 188).  
HCV particle formation is a complicated and incompletely understood 
process. This process is tightly linked to lipid metabolism. Interestingly, many 
NS-proteins of HCV take part in particle assembly, indicating links with RNA 
replication. Particle formation is started by the interaction of genomic RNA 
with the capsid protein (189). Locating genomic RNA into LD and the smooth 
ER is crucial for assembly (Fig. 2B). HCV particles form by budding to the 
luminal side of smooth ER membranes containing E1/E2 heterodimers. The 
particles are transported to the plasma membrane via the very low-density lipo-
protein synthesis/secretion pathway. During this process, complex modifica-
tions of formed particles occur. Infectious particles are released by exocytosis 
(190–192). It is also known that HCV can infect neighbouring cells without 
actually exiting to the extracellular space (Fig. 2B). The mechanism that under-
lies this cell-to-cell spread is not yet known; however, it has been shown that 
this type of spreading is resistant to the presence of neutralizing monoclonal 
antibodies (193–195). 
 
 
1.4.5. Historical and current therapies for HCV infection  
The aim of anti-HCV treatment is to reach a sustained virological response 
(SVR). An SVR is defined as the condition in which 24 weeks after the end of 
treatment, no virus can be detected in the patient’s blood. Until 2011, the main 
standard of care (SOC) for chronic HCV infection was based on combined 
treatment with IFN-α (or pegIFN-α) and ribavirin. Depending on the HCV GT, 
the SOC treatment lasted from 24 to 48 weeks (196, 197), and its efficiency 
depended on host genetics (105) and on the HCV GT. In general, an SVR was 
achieved for only 40–50% of GT1 treatment-naïve patients; in contrast, an SVR 
was achieved in approximately 80% of infections with other GTs. PegIFN-α 
and ribavirin are broad-spectrum antivirals (see 1.3.1, 1.3.2), and their use is 
associated with various side effects.  
Boceprevir and telaprevir, which are inhibitors of the HCV GT1 NS3/4A 
protease (mimic the substrate of the enzyme), became the first approved DAAs 
against HCV. The approval of these inhibitors in 2011 allowed the use of triple 
therapy: the new inhibitors were used in combination with the former SOC. The 
use of these inhibitors raised the SVR rate to 60% in the treatment of experi-
enced patients compared to a 20% SVR for the control group (198, 199). In the 
case of treatment-naïve HCV GT1 patients, the rate of SVR achieved by triple 
therapy was approximately 70–80%. The use of these DAAs did not alleviate 
the side effects of the SOC; instead, new adverse effects (such as rash in the 
case of telaprevir) were observed. Thus, the first DAAs resulted in a clear 
improvement of HCV treatment but not a breakthrough. 
The real breakthrough – IFN-free treatment with oral drugs with pan-geno-
type activity – was achieved recently. The cornerstone of this therapy is the 
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nucleotide analogue NS5B polymerase inhibitor sofosbuvir, which was devel-
oped by Pharmasset/Gilead and is marketed as a mixture with ribavirin under 
the brand name SOVALDI® (57). Unlike the first-generation protease inhibi-
tors, sofosbuvir is active against all HCV GTs (although its activity against GT3 
is somewhat lower). Most importantly, sofosbuvir shows a very high barrier of 
genetic resistance. Mutants resistant to this drug are rare, and such mutations 
are associated with a great fitness cost. Furthermore, the treatment is con-
siderably shorter (24 weeks for GT3 and 12 weeks for other GTs) and can be 
applied both to treatment-naïve and experienced patients, with or without liver 
fibrosis/cirrhosis (57, 200).  
In the last two years, a few more DAAs targeting HCV have received 
approval for clinical use. In addition to the NS3/4A protease and the NS5B 
polymerase, the NS5A protein has been successfully targeted (Fig. 2C). The list 
of approved DAAs (as October, 2015) includes nine compounds: 
- Sofosbuvir, a nucleotide analogue inhibitor of NS5B 
- Dasabuvir, a non-nucleoside inhibitor of NS5B 
 
Thus, there are two classes of NS5B inhibitors with different mechanisms of 
action. Nucleotide inhibitors act as pseudo-substrates of the enzyme, while non-
nucleoside inhibitors act by creating unfavourable conformational changes in 
the proteins (201–203).  
- Boceprevir and telaprevir, which are first-generation NS3/4A inhibitors. 
These compounds are linear peptidomimetics that bind covalently to the 
NS3/4A protease and block the substrate binding sites (204, 205).  
- Simeprevir and paritaprevir, which are second-generation protease inhibi-
tors. These inhibitors are macrocyclic compounds that do not bind covalently 
to the enzyme (206, 207).  
- Ledipasvir, ombitasvir and daclatasvir target NS5A. These compounds have 
demonstrated pan-genotypic activity and a relatively high barrier to resis-
tance. Curiously, the precise mechanism of action of these inhibitors is not 
known. It is proposed that these inhibitors can either regulate NS5A 
phosphorylation and/or regulate lipid metabolism. Regardless of the mecha-
nism, these compounds are among the most efficient inhibitors and greatly 
reduce HCV replication (208).  
 
As the number of approved DAAs has increased rapidly, precise DAA combi-
nations have been developed to achieve the safest and most efficient outcomes 
(209). The currently approved combinations include: 
- HARVONI®: a mixture of sofosbuvir and ledipasvir (210);  
- VIEKIRA®: a mixture of ombitasvir, paritaprevir, dasabuvir and ritonavir 
(not an HCV inhibitor; instead, it is an inhibitor of CYP3A4 enzymes) (211).  
 
In addition, some new DAAs can be used in combination with pegIFN-α and/or 
ribavirin. Examples of such DAAs are simeprevir (212) and daclatasvir; these 
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drugs can also be combined with sofosbuvir. Many of these combinations 
exhibit SVR rates of up to 99%, and in the case of IFN-free combinations, the 
side-effects are drastically reduced (100). With new drugs in the pipeline (see 
1.4.6), the number of successful drugs/drug combinations will continue to 
increase. However, the persisting problem is the cost of treatment, which has 
increased considerably (~20,000–30,000 US dollars in 2010 compared to 
84,000–168,000 US dollars in 2015). This increase has boosted interest in the 
development of more affordable treatments for HCV infection.  
 
 
1.4.6. Further development of new anti-HCV therapies  
As reviewed above, the progress in HCV treatment in the last 5 years has been 
tremendous. New DAAs have brought SVR rates near 100% and reduced the 
side effects caused by pegIFN-α and ribavirin. Nevertheless, there are still mul-
tiple aspects to resolve and improve, such as the increased costs of treatment. 
The development of DAAs has also been biased towards the treatment of GT1 
patients; consequently, the treatment efficiencies for patients infected with other 
GTs are lower. Patients with severe cirrhosis and post-transplantation patients 
are still in need of improved treatment. Another aspect is the acquired resistance 
of HCV to DAAs; due to the relatively short history of these treatments, the 
possible magnitude of the problem is not yet known. Therefore, further research 
and development in the area of HCV inhibitors is still needed. 
Most new inhibitors in the late stages of clinical trials target the same pro-
teins that are targeted by already approved DAAs (Fig. 2C). 
- there are several promising non-nucleoside inhibitors of NS5B, including 
beclabuvir (phase III) and GS-9669 (phase II); 
- grazoprevir is a new macrocyclic NS3/4A inhibitor that has entered phase III 
trials; the same is true for the non-macrocyclic (tripeptide) NS3/4A inhibi-
tors faldaprevir and asunaprevir;  
- of the new NS5A inhibitors, elbasvir has entered phase III trials; samatasvir 
and ravidasvir (PPI-668) have been tested in phase II trials. 
 
Based on these (possibly incomplete) data, it is not hard to predict that the num-
ber of anti-HCV DAAs will increase. However, the list of targets does not 
appear to expand. There are no approved drugs (or compounds in late stages of 
development) that target the NS4B and p7 proteins or the helicase activity of 
NS3. Multiple in vitro studies have shown that these proteins can be targeted to 
reduce the release of HCV particles. Thus, clemizole and its analogues target 
NS4B RNA binding activity. Anguizole and structurally related compounds 
bind NS4B and inhibit the lipid vesicle aggregation that is characteristic of 
HCV infection. These are only some examples of compounds targeting HCV 
NS4B (213).  
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One group of antivirals that has received relatively little attention to date are 
host targeting antivirals (HTA), which target factors with proviral effects in the 
HCV infection cycle. Only a few such inhibitors have been tested in clinical 
trials. Examples of such compounds are cyclophilin inhibitors (alisporivir) 
(214) and ASOs that target liver-specific mir-122 (miravirsen) (215). These 
inhibitors are able to supress different HCV GTs and possess high resistance 
barriers. Other types of HTAs include antibodies that target the extracellular 
domains of claudin (216) and compounds that inhibit different steps of the cho-
lesterol biosynthesis pathway (217). 
 
 
1.4.7. Status and perspectives of anti-HCV vaccine development 
The genetic diversity of HCV and its ability to escape the immune system have 
hampered vaccine development; as a result, no vaccine is available for HCV. 
Another obstacle is that in natural infection, HCV generally does not activate an 
immune response to an extent that allows the efficient elimination of the virus. 
Based on the experience acquired from other antiviral vaccines, it is clear that 
successful vaccination should induce a strong neutralizing antibody and (pref-
erably) also T-cell responses. Ideally, these responses should target all HCV 
GTs or at least a range of HCV GTs. However, given the very low sequence 
conservation, a pan-genotypic HCV vaccine may not be possible. Despite all of 
these difficulties, several anti-HCV vaccine candidates have reached clinical 
trials.  
In contrast to the majority of viral vaccines, most HCV vaccines have been 
designed not as prophylactic vaccines but as therapeutic vaccines. Such vac-
cines aim to eradicate already established chronic HCV infection and are often 
tested in combination with antiviral therapy (218, 219). In addition, the use of 
therapeutic vaccines may result in long-lasting immunity that will prevent (or 
reduce) re-infection. Given the spread of HCV in certain risk groups (such as 
intravenous drug users), long-lasting immune protection may represent an 
important benefit, as the probability of re-infection (with the same or different 
HCV GT) is high. One of these vaccine candidates, E1E2/MF59, contains the 
E1 and E2 proteins together with the adjuvant MF59C.1 (oil (squalene)-in-water 
emulsion). A clinical trial of this vaccine in combination with pegIFN-
α/ribavirin treatment resulted in a reduced viral load (220).  
The progress achieved in the area of anti-HCV drug development has not 
reduced the importance of preventing HCV infection. First, as primary HCV 
infections generally do not cause symptoms, they are usually unnoticed and 
patients turn to doctors only when serious liver damage has already occurred. 
Second, the prevention of infection is likely to be a much less expensive option 
than the treatment of chronic HCV infection. Finally, at least in risk groups, 
there is a possibility of re-infection among previously treated patients. There-
fore, the development of a prophylactic vaccine has clearly maintained its 
importance. However, to date, few vaccine candidates of this type have been 
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generated and tested in clinical trials. One example of this strategy is a vaccine 
that aims to induce cellular immunity by using heterologous virus vectors that 
express parts of the HCV polyprotein. Such vaccine candidates are based on a 
replication-defective simian adenoviral vector (ChAd3) and modified vaccinia 
Ankara based vectors expressing the NS3, NS4, NS5A, and NS5B proteins of 
HCV GT1b. Clinical trials have shown that this vaccine induces durable, broad, 
sustained, and balanced T cell responses (221). These findings are encouraging 
and indicate the potential of prophylactic HCV vaccines.  
 
 
1.5. Chikungunya virus (family Togaviridae) 
Chikungunya virus (CHIKV) belongs to the genus Alphavirus family Toga-
viridae. To the date approximately 30 different alphaviruses have been de-
scribed. These viruses are found on every continent and infect a broad range of 
hosts, from invertebrates to humans. Alphaviruses are mainly arboviruses, and 
they spread between vertebrate hosts by using invertebrate vectors (mainly mos-
quitos) (222, 223). Many alphaviruses infect humans and can cause diseases; 
however, before 2005, these viruses were not considered to have significant 
medical importance. This view changed during the last decade, as one alpha-
virus, CHIKV, has spread rapidly and travelled beyond its usual hotspots, af-
fecting millions of people (224, 225). There are three genotypes (sometimes 
referred to as lineages) of CHIKV: East Central South African (ECSA), Asian, 
and West African (222). The closest relative of CHIKV is o’nyong’nyong virus 
(ONNV) (222). Other alphaviruses that are pathogenic to humans and cause 
fever, rash, arthritis and myalgia (typical symptoms of CHIKV, see 1.5.4) are 
Ross River virus (RRV) and Barmah Forest virus (BFV) in Australia/Oceania 
and the widespread Sindbis virus (SINV) (226). New World alphaviruses, such 
as Western, Venezuelan and Eastern equine encephalitis viruses (WEEV, 
VEEV and EEEV), primarily cause encephalitis (227).  
CHIKV is transmitted to humans by Aedes mosquitoes. The mosquitoes 
acquire infection by feeding on infected humans (or animals). CHIKV infection 
in mosquitoes is persistent and is thought to be non-pathogenic (or largely non-
pathogenic) (228). The most common vector for CHIKV is the tropical mos-
quito Aedes aegypti. Aedes albopictus mosquitoes can also transmit CHIKV, 
albeit typically less efficiently. However, Aedes albopictus tolerates colder 
climates and is more widespread in urban areas, and the area of this mosquito 
has rapidly expanded due to climate changes and the globalized economy 
(transport of different goods) (229). Furthermore, as highlighted below, CHIKV 
of the ECSA genotype can specifically adapt to this vector. 
CHIKV was first isolated in Tanzania in 1952 (230), and for nearly half of a 
century, the virus remained largely unstudied. An outbreak of unprecedented 
magnitude started in 2004/2005. This outbreak was caused by the ECSA geno-
type of the virus (231), which acquired a single aa change in the virus envelope 
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glycoprotein E1 (Ala226 to Val) during the outbreak. This change greately 
increased the infectivity of the virus for Aedes albopictus midgut cells (232). 
Additional mutations that facilitate infectivity of CHIKV for Aedes albopictus 
even further were also documented (229, 233). These changes were sufficient to 
allow a vector switch, which led to epidemics on Indian Ocean islands (in-
cluding La Reunion) in 2005 (234, 235) and subsequently in South-East Asia. 
Due to increased travel, smaller outbreaks also occurred in Europe: in 2007 in 
Italy (236) and in 2011 in France (237). In 2013, CHIKV reached the Caribbean 
islands and Central America, and local circulation of the virus was established 
(238–240). The Asian genotype of CHIKV, which is responsible for this out-
break (241), cannot adapt to Aedes albopictus as easily as the ECSA genotype 
(242). Consequently, CHIKV transmission in the region occurs mostly via 
Aedes aegypti mosquitoes. The current worldwide distribution of CHIKV is 
shown in Fig. 3. 
 
 
 
Figure 3. Global distribution of CHIKV as of October 2015. Countries and territories 
with local transmission are shown in dark green.  
(http://www.cdc.gov/chikungunya/geo/index.html Permission obtained from the Centers 
for Disease Control and Prevention.) 
 
 
1.5.1. CHIKV virion and genome organization  
Alphaviruses have enveloped virions with very regular structures. The external 
virion diameter is approximately 65 nm and it contains an inner nucleocapsid 
with a diameter of approximately 40 nm (243). The nucleocapsid contains a 
single RNA genome and 240 copies of the capsid protein (T4 symmetry). The 
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nucleocapsid is surrounded by a lipid bilayer derived from the cellular plasma 
membrane (Fig. 4A). The envelope is tightly packed with viral glycoproteins 
that form 80 spikes. Each spike consists of three E1-E2 heterodimers. Thus, 
similar to the capsid, the outer glycoprotein layer also exhibits T4 icosahedral 
symmetry (244). The 3D structure of E1-E2 dimers of CHIKV has been re-
solved and in combination with excellent cryo-EM data, has resulted in recon-
struction of a high-resolution structure of CHIKV virions (245). 
Figure 4. A. Schematic representation of a CHIKV virion. B. CHIKV lifecycle: 
cytosis 2. Nucleocapsid release into the cytoplasm, followed by the synthesis of the 
non-structural polyprotein 3. Replication complex (spherule) formation coincides with 
negative-strand RNA synthesis. Replication complexes are internalized, and CPV-I 
structures are formed 4. Synthesis of genomic (42S) and subgenomic (26S) RNAs 5. 
1. Binding to the receptor and internalization of the virion via clathrin-dependent endo-
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Nucleocapsid assembly 6. Processing and maturation of virion glycoproteins. 7. 
Budding of new virions C. Schematic presentation of the CHIKV genome.  
The CHIKV genome has a length of approximately 12 kb. Similar to cellular 
mRNA, the genome contains a cap structure at its 5’ end and a 3’ poly(A) tail 
(Fig. 4C). The genome contains two ORFs. The 5’ ORF (roughly 2/3 of the 
CHIKV genome) encodes precursor(s) of the viral non-structural proteins 
(nsPs), while the 3’ ORF encodes a precursor of the viral structural proteins. 
The CHIKV genome has a short 5’ UTR, while the 3’ UTR contains a variable 
number of repeated motifs and therefore its length varies considerably between 
different CHIKV genotypes and isolates (246). The third non-coding region is 
located between two ORFs. This genome organization is shared by all alphavi-
ruses. There are four conserved sequence elements (CSE) that are essential for 
genome replication and transcription and are highly conserved in all alphavi-
ruses. CSE1 is located in the 5’ UTR and is essential for the synthesis of nega-
tive- and positive-strand RNAs (247). CSE2 (also known as 51 b element) is 
located in the region that encodes the N-terminal part of nsP1. This element 
contains two hairpin structures, which are dispensable for replication in mam-
malian cells but crucial for replication in insect cells (248, 249). CSE3 is 
located at the end of the coding region of nsP4 and is included in the subge-
nomic (SG) RNA promoter that is used for the synthesis of mRNA for structural 
proteins (250, 251). CSE4 is located before the poly(A)tail and contains the 
start site for negative-strand RNA synthesis (252, 253). 
 
 
1.5.2. Functions of CHIKV-encoded proteins  
Current knowledge about CHIKV protein functions is fragmented. Multiple 
functions have been demonstrated for proteins of other alphaviruses, and it is 
often assumed that CHIKV proteins carry the same activities and functions. 
This assumption is likely to be true for conserved enzymatic or structural 
properties. Other functions, such as interactions with the host, may not be con-
served. In the brief review below, I will concentrate on the functions that have 
either been directly demonstrated for CHIKV proteins or have been revealed for 
proteins of other alphaviruses but almost certainly also apply to their CHIKV 
counterparts. 
Non-structural protein 1 (nsP1) is essential for the synthesis of negative-
strand RNAs (254). This protein has methyltransferase and guanylyltransferase 
activities that are required for the synthesis of the cap structure at the 5’ end of 
the virus genome and SG mRNA using unique (but common for alphavirus-like 
RNA viruses) pathway (255–257). Alphavirus replication complexes are 
anchored to cellular membranes via an amphipathic helix located in the central 
part of nsP1 (255, 258–260). Palmitoylation of nsP1 enhances its binding to 
cellular membranes (261). In infected cells, part of nsP1 is located in the plasma 
membrane, where it counteracts the effects of the cellular antiviral protein 
tetherin (262, 263).  
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Non-structural protein 2 (nsP2) is a multifunctional protein that performs 
different tasks. The N-terminal region (aa residues 1-470) of nsP2 possesses 
NTPase and 5'-RNA triphosphatase activities. The full-length nsP2 also has 
RNA helicase activity that unwinds double-stranded RNA molecules in the 5’-
3’ direction. The significance of this activity for virus replication is not pre-
cisely known. nsP2 also has an opposite, RNA matchmaker activity (264, 265). 
The C-terminal region of nsP2 is a cysteine papain-like protease that is respon-
sible for the processing of the viral non structural polyprotein (266). nsP2 is 
also a key regulator of virus-host interactions. Part of nsP2 is transported to the 
nucleus, where (in the case of vertebrate cells) it causes the degradation of 
cellular RNA polymerase II and shuts down host cell transcription (267). Dif-
ferent mutations in nsP2 have been shown to reduce the cytotoxicity of CHIKV 
infection (268, 269). In addition, nsP2 interferes with interferon-induced sig-
nalling and the unfolded protein response (270, 271).  
Non-structural protein 3 (nsP3) is the least studied replicase protein of 
alphaviruses. This protein contains three domains: the macro domain, the Zn 
binding domain (ZBD) and the C-terminal hypervariable domain (HVD). The 
macro- and Zn binding domains are conserved between alphaviruses, and the 
crystal structures of these domains have been resolved (272, 273). The macro 
domain of some (but not all) alphaviruses has weak adenosine di-phosphoribose 
1''-phosphate phosphatase activity (272), which unlikely has any significance for 
alphavirus infection. Most likely this activity reflects another, yet to be dis-
covered, enzymatic activity of this domain. The ability of the macro domain (and 
the Zn binding domain) to bind RNA is also important for the virus (273). The 
macro domain can also bind ADP-ribose, poly(ADP-ribose) and poly(ADP-
ribose) polymerase 1 (274, 275). This property suggests a role of nsP3 in the 
suppression of the cellular anti-viral response, as IFN-stimulated poly(ADP-
ribose) polymerases are powerful inhibitors of alphavirus infection (276, 277). 
The HVD of nsP3 is intrinsically disordered. With the exception of several 
conserved motifs, no sequence similarity between corresponding domains from 
different alphaviruses can be observed (223). The HVDs of Semliki Forest virus 
(SFV) and SINV are heavily phosphorylated. It has been established that in the 
case of the nsP3 of SFV, approximately 16 aa residues, which are located at the 
beginning of HVD, are phosphorylated. For SINV, it has been shown that the 
reduction of nsP3 phosphorylation decreases the replication of viral RNA. 
Moreover, in the case of SFV, the deletion of the phosphorylated region results 
in a loss of neurovirulence (278). Interestingly, the phosphorylation of nsP3 has 
not yet been experimentally demonstrated for CHIKV. Most likely, this func-
tion exists, but its significance for different viruses is not necessarily the same.  
There are also other functions of HVD that are similar between CHIKV and 
at least some other alphaviruses. Thus, the HVDs from SFV and CHIKV in-
teract with cellular G3BP proteins. This interaction interrupts the formation of 
stress granules and is also important for the initial stages of CHIKV infection 
(279–284). It is reasonable to assume that the HVD also contains motifs re-
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quired for interactions with other cellular proteins. Some of these interactions 
may be conserved for all alphaviruses, other interactions may be conserved for 
some alphaviruses and some interactions may be unique to a specific virus. 
Several of these interactions have been revealed, and in a few cases, their bio-
logical significance has been demonstrated (285, 286). Taken together, even 
though the precise functions of nsP3 remain largely unrevealed, it is clear that 
this protein plays a critical role in the correct formation and localization of 
replication complexes (259) and is central for alphavirus-host interactions. 
Non-structural protein 4 (nsP4) is highly conserved among alphaviruses. 
Very little is known about the functions of CHIKV nsP4, because in infected 
cells, this protein is present in very low amounts. Upon expression in the form 
of a recombinant protein, nsP4 aggregates and is extremely hard to solubilize 
(unpublished observation of our lab). Therefore, most of the available infor-
mation regarding the functions of alphavirus nsP4 originates from studies of 
SINV. It has been demonstrated that nsP4 is an RNA-dependent RNA poly-
merase (RdRp) of alphaviruses that is responsible for viral RNA replication 
(223, 287). This protein also possesses terminal adenylyl-transferase activity 
that is essential for the synthesis/repair of the poly(A) tails of viral positive-
strand RNAs (288). This protein functions together with other ns proteins (259, 
289, 290) and host proteins (259, 291). nsP4 has also been shown to have non-
replicative functions. It was recently shown that nsP4 of CHIKV is essential for 
the suppression of the ER stress response that limits virus replication (292). 
Alphavirus structural proteins are translated from SG RNA in the form of 
a structural polyprotein (C-E3-E2-6K-E1). This precursor is cleaved into mature 
proteins by virus- and host-encoded proteases. The capsid protein has protease 
activity and cleaves itself from the rest of the structural polyprotein. In addition 
to the binding of the viral genome and the formation of the nucleocapsid, the 
capsid protein participates in the acquisition of the virion envelope by binding 
to the E2 glycoprotein (293, 294). E1, E2 and E3 are all glycosylated mem-
brane proteins. E1 and E2 form spikes on the virion surface and are essential for 
virion assembly. E3 is not a transmembrane protein and remains associated with 
mature virions of some (such as SFV) alphaviruses. E2 is a palmitoylated trans-
membrane protein (295–297) and is responsible for the binding of the cellular 
receptor (298). E1 is the fusion protein of alphaviruses (299). 6K is also 
included in virions, but the precise functions of this protein are not known 
(300). The final structural protein, transframe (TF), is produced by a ribo-
somal frame-shift that occurs in the region encoding the 6K peptide. This pro-
tein affects the pathogenicity of SINV infection and, to some extent, virus 
production in cell culture. However, the functions of this protein remain largely 
unknown (301, 302). 
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1.5.3. CHIKV replication cycle 
The CHIKV replication cycle is similar to that of other alphaviruses (Fig. 4B). 
Infection starts with E2-mediated binding of the virion to an unknown cellular 
receptor (or receptors). Binding is followed by rapid internalization of the virion 
into endosomal vacuoles. Due to the low pH in the endosomes, E1-E2 hetero-
dimers dissociate and the viral E1 protein undergoes irreversible conformational 
changes that allow fusion between the endosome and the virion membranes 
(245). After membrane fusion, a free nucleocapsid enters the cytoplasm and 
becomes disassembled, and the genomic RNA is released. 
After entering the cell, the 5’ two-thirds of the genome is translated into the 
non structural polyprotein (P1234). P1234 attaches itself to the inner surface of 
the plasma membrane. At the same time, the switch from genome translation to 
replication should occur. The mechanism of this process is unknown, although 
it has been suggested that this process may be mediated by the action of host 
proteins, possibly G3BPs (283). RNA replication is associated with tightly 
regulated processing of P1234; interruption of this process will result in the loss 
of infectivity or reduced viral fitness. First, nsP4 is cleaved from P1234 by the 
protease activity of the nsP2 region. The products of this reaction (P123 and 
nsP4) form an early replication complex, which synthesizes negative-strand RNA 
(anti-genome). Most likely, only one negative-strand RNA is made and it forms 
a duplex with the genomic RNA (303). This step must occur in the vicinity of 
the plasma membrane and coincides with formation of specific structures, 
membrane invaginations (called spherules), which contain viral RNA and 
replicase proteins (304, 305). After negative-strand RNA synthesis is com-
pleted, P123 is processed into nsP1 and the P23 polyprotein, and the final cleav-
age of P23 into nsP2 and nsP3 follows almost instantly. This cleavage results in 
the formation of a late replicase (nsP1+nsP2+nsP3+nsP4) that uses negative-
strand RNA (or, more likely, double-stranded RNA) as a template and synthe-
sizes new genomes and SG RNAs (303). SG RNAs are made in excess in com-
parison to viral genomes and are used for the synthesis of structural proteins. 
During the early stages of infection, the newly made genomic strand enters the 
replication cycle, and the number of functional replicase complexes increases. 
During the later stage of infection, the accumulation of free nsP2 results in a 
change in the P1234 processing pathway, preventing further formation of early 
(and consequently also late) replicase complexes (306). The already formed 
replicase complexes remain active, become internalized via phosphati-
dylinositol-3-kinase-, actin-, and microtubule-dependent transport (305) and are 
ultimately located in virus replication organelles – cytopathic vacuoles type I 
(CPV-I). 
The packaging signal of CHIKV RNA is located in the region that encodes 
the protease domain of nsP2 (307). The interaction of capsid proteins and ge-
nomic RNAs results in the formation of nucleocapsids, which are then trans-
ported to the cell membrane. Budding is triggered by the interaction between 
the capsid protein and the E2 envelope protein (308, 309).  
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1.5.4. Pathology associated with CHIKV infection 
CHIKV is transmitted via a mosquito bite and typically has an incubation time 
of between two and six days. Only 15% of CHIKV infections are asympto-
matic. The typical symptoms of infection include high fever (~40°C), headache, 
back pain, myalgia, vomiting, nausea, conjunctivitis, arthralgia and rash (310, 
311). CHIKV infection is characterized by high viremia, with viral titres 
ranging from 105 to 1012 pfu/ml (plaque forming units per millilitre). High vire-
mia is a pre-requisite for mosquito transmission and usually lasts for up to five 
days (only then can mosquitoes acquire the virus). At this stage, viral repli-
cation is controlled by the innate immune response, and the severity of infection 
depends on the expression of several antiviral genes, including viperin and 
TLR3 (312, 313). Most symptoms of acute infection are cleared after several 
weeks, but in many cases, chronic symptoms (most commonly arthralgia/ 
arthritis) of different severity may occur. Alphavirus-induced arthritis primarily 
affects peripheral joints: fingers, wrists, elbows, toes, ankles and knees (311, 
314). For CHIKV infection, it has been estimated that approximately 40% of 
patients develop a chronic disease (315). Chronic arthritis is more likely to 
occur in elderly people and in patients who have higher viral loads during the 
acute phase of infection (316). Additionally, patients with a previous history of 
rheumatic arthritis or joint injuries are more prone to suffer from severe CHIKV 
infection and subsequent chronic arthritis (317). 
 
 
1.5.5. Development of antivirals and vaccines against CHIKV 
No licensed vaccines or specific antivirals against CHIKV infection are 
available. Therefore, the treatment of CHIKV infection aims to relieve symp-
toms. There are also some broad-spectrum antivirals that can be used for the 
treatment of CHIKV infection. Some compounds that were developed for the 
treatment of other viral infections have also shown some antiviral efficiency 
towards CHIKV. However, the achieved benefit in the treatment of real infec-
tions (in patients) has been low, and in most cases, the mechanism that underlies 
the observed antiviral activity is unknown. The exception to this rule is the 
polymerase inhibitor favipiravir, which shows anti-CHIKV activity and clearly 
acts as an inhibitor of nsP4 (62). Other active agents that exhibit activities 
towards CHIKV are IFN-α and 6-azauridine (318). Ribavirin can act both as a 
nucleotide analogue and as an inhibitor of purine nucleotide biosynthesis. It has 
been hypothesized that reduced intracellular levels of GTP may impair the 
guanylyl transferase function of nsP1 (318). Chloroquine (68) and arbidol are 
thought to disrupt CHIKV entry (319).  
The screening of libraries of synthetic and natural compounds has resulted in 
the identification of multiple hits with anti-CHIKV activity. The mechanisms of 
action of these compounds are typically unknown; at best, educated guesses 
concerning the possible targets can be made (based on molecular docking). For 
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example, several compounds that presumably target the nsP2 protease have 
been discovered (320, 321) or, in one case, specifically designed (322). The 
mechanisms of action of natural compounds with anti-CHIKV activity, such as 
silymarin (323), harringtonine (324), suramin (325) and trigocherrierin A (326), 
are not known, although it is possible that these compounds are HTAs. Few 
other compounds that target essential host factors for CHIKV infection have 
been described (291, 327).  
Although no licensed vaccine is available for CHIKV, the existing data 
strongly suggest that the development of an efficient vaccine for this virus is not 
only possible but also achievable in the relatively near future. The first attempts 
to generate formalin-inactivated CHIKV vaccines date back to 1971 (328). 
Live-attenuated vaccine development was performed by the US Army. The 
vaccine was obtained from a CHIKV strain isolated in Thailand. Propagation of 
the virus in cell culture (unfortunately, the exact passage history is unknown) 
resulted in an attenuated virus that is designated as CHIKV TSI-GSD-218. This 
vaccine was found to be efficient, but immunized volunteers suffered from side 
effects (mild to moderate arthralgia) (329). It was subsequently confirmed that 
the attenuation was based on only two mutations in the E2 protein and that the 
“side effects” may have in fact been caused by viruses acquiring reversions at 
these positions (330, 331). However, many novel CHIKV vaccine candidates 
have been tested in animal models (mostly in mice, fewer in non-human pri-
mates), and a few of these candidates are in clinical trials.  
Multiple approaches have been used to generate new CHIKV vaccine candi-
dates, from classical inactivated vaccines to the development of modern attenu-
ated, DNA, subunit and chimeric vaccines. In one approach, the SG promoter of 
CHIKV was substituted with the IRES element from encephalomyocarditis 
virus positioned between two ORFs in such a way as to trigger the expression of 
structural proteins (332, 333). Recombinant viruses, which lack regions en-
coding the 6K protein, a part of the nsP3 region (334) or the transmembrane 
part of the E2 protein (335), have been constructed and tested. DNA vaccines 
have been designed to express the complete virus genome, the virus genome 
lacking the capsid protein region or just one or several structural proteins of 
CHIKV (334, 336). Subunit vaccines based on the E1 and E2 proteins or on 
CHIKV VLPs assembled in mammalian or insect cells have been used (243, 
336, 337). Additionally, chimeric viruses expressing CHIKV antigens have 
been constructed using measles virus (338), adenovirus (339), VSV (340), 
MVA (341–343) or other alphaviruses (344) as vectors. With rare exceptions 
(mostly observed when single proteins or constructs expressing single proteins 
have been used), all of these vaccine candidates elicit strong anti-CHIKV 
immune responses. Furthermore, in most cases, the antibody response generated 
by the vaccine candidates is neutralizing and protects against challenge with 
wild-type CHIKV of the same (most of these vaccine candidates are based on 
the ECSA genotype) or different genotype. Progress in the development of 
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novel anti-CHIKV vaccine candidates has also been recently reviewed (re-
viewed in (319)). 
Taken together, the differences from the area of anti-HCV vaccine develop-
ment (see 1.4.7) are striking. There are many (maybe too many) promising vac-
cine candidates for CHIKV, and the main issues that remain are the costs of 
clinical development and the ever-present question of rational use of the vac-
cine, as the unpredictable nature of CHIKV outbreaks makes it very difficult to 
estimate where and when the virus will strike next.  
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2. OBJECTIVES 
HCV and CHIKV represent serious threats to human health and wellbeing. 
CHIKV is spreading rapidly and affects millions of people. There is currently 
no vaccine to prevent CHIKV infection. HCV causes chronic infection in more 
than one hundred million people. Even with revolutions in anti-HCV therapy, 
additional and affordable treatments are needed. It remains essential to develop 
novel and efficient vaccine/antiviral strategies to counteract the emerging resis-
tance of chronic infections and infections caused by new viruses. 
The objectives of the studies included into this thesis were: 
1. To provide experimental verification of the efficiency and to analyse the side 
effects of novel anti-HCV drug candidates, which are low molecular weight 
inhibitors of the HCV NS3/4A serine protease that were selected by in silico 
screening.  
2. To experimentally validate an ASO-based antiviral strategy targeting the 
HCV coding region. The aspects to be analysed included the development of 
a method for ASO target selection, the experimental validation of the impact 
of 8-oxo-dG modification on the basic properties of ASOs and antiviral ac-
tivity and to reveal the molecular basis of their efficacy (or lack of efficacy).  
These objectives were oriented to validate and improve novel approaches 
and technologies, confirm their applicability and/or to highlight problems 
associated with these approaches.  
3. To test the genetic stability of novel attenuated vaccine candidates developed 
against CHIKV. To analyse the molecular basis of virus attenuation that was 
achieved by introducing deletions in the HVD of the nsP3 and to study the 
biological functions of this region in CHIKV-infected cells. 
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3. MATERIALS AND METHODS 
The evaluation of the cytotoxicity of seven in silico predicted compounds using 
the xCELLigence system is explained in publication I, Supplementary Material 
3. The materials and methods for experiments conducted with ASOs targeting 
HCV in a cell culture system and using cell-free assays are described in publi-
cation II. Detailed descriptions of the materials and methods used in CHIKV 
studies are provided in publications III and IV. The methods used to obtain 
unpublished data are provided below. 
 
HCV inhibition and cell cytotoxicity assay for in silico designed compounds  
All analysed compounds (19145, 32387, 24757, 32385, 23330, 23332, and 
31356) were dissolved in dimethyl sulfoxide (DMSO). DMSO is a widely used 
solvent and has been shown to be non-toxic (depending on the cell line) at final 
concentrations of 0.1–0.5%. In the case of the Huh-luc/neo-ET cell line, we 
found that the well-tolerated (no cytotoxic or cytostatic effect was observed) 
concentration of DMSO was 0.2%. Therefore, 0.2% DMSO in growth medium 
was used as a vehicle control, and all compounds were applied to cells at a final 
concentration of 0.2% DMSO.  
To analyse anti-HCV properties, the dissolved compounds were diluted in 
growth medium. We also ensured that the compounds did not precipitate during 
the preparation of the dilutions. Medium containing the compounds was then 
applied to Huh-luc/neo-ET cells. At the selected time points, the cells were 
lysed, and luciferase activity and total protein concentrations were measured 
and normalized to cells treated with the vehicle control. 
The cytotoxicity of the compounds was measured using the 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) method. Inhibitors 
were added to the cells (grown in the wells of a 96-well cell culture plate) at the 
indicated concentration, and the cells were incubated in the medium for 48 h. 
The MTT reagent was added to the wells at a final concentration of 0.5 mg/ml, 
and the plates were incubated at 37°C in a 5% CO2 atmosphere for 2 h. Subse-
quently, the supernatant was removed, 100 μl of DMSO were added per well 
and the plates were shaken gently for 15 min. The optical densities were 
measured at 540 nm using a microplate reader (Sunrise Tecan, Magellan™). 
 
Virological methods 
For infectious centre assay (ICA), 1 µg of in vitro synthesized RNA was 
electroporated into 8×106 BHK-21 cells. Ten-fold serial dilutions of electro-
porated cells were seeded into six-well tissue culture plates that contained 
1.5×106 BHK-21 cells per well. After incubation for 2 h at 37°C, the cell culture 
medium was aspirated, and the cells were overlaid with 2 ml of carboxymethyl 
cellulose (CMC)-containing growth medium (final concentration of 0.8% CMC) 
supplemented with 2% fetal calf serum (FCS). Plaques were stained with crystal 
violet after 2–3 days of incubation at 37°C.  
43 
The plaque assay, combined with an analysis of the genetic homogeneity of 
the viral stocks and the rescued viruses, was carried out as follows. Monolayers 
of BHK-21 cells were grown in 6-cm cell culture plates and infected with 20–30 
pfu of the collected viruses. After 1 h of incubation at 37°C, the inoculum was 
removed, and the cells were covered with growth medium containing 1% aga-
rose and 2% FCS. At 48 h p.i., another layer of 1% agarose, which contained a 
neutral red staining solution, was added. Twelve hours later, 5 plaques were 
isolated. The viruses were eluted with 0.5 ml of growth medium and used to 
infect new BHK-21 cells in a 24-well plate. At 24 h p.i., the total RNA was 
extracted from each well infected with the obtained virus using the TRIzol 
reagent (Life Technologies). Reverse transcription was carried out using a first-
strand cDNA synthesis kit (Thermo Scientific). CHIKV- or SFV-specific cDNA 
fragments were PCR-amplified using pairs of primers that matched the non-
structural part of the virus genomes and sequenced.  
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4. RESULTS AND DISCUSSION 
4.1. Novel technologies for the development  
of antiviral drugs 
The first anti-HCV DAAs were approved 4 years ago (22 years after the dis-
covery of the virus). Although those DAAs were promising, they were 
accompanied by side effects and virus-acquired resistance. The real break-
through in anti-HCV therapy was achieved recently with new DAAs that have 
minimal side effects and in some cases, a high barrier to resistance. These new 
therapies are expensive, and the appearance of new resistant HCV strains 
remains in question. Therefore, new efficient and cost-effective treatments are 
still needed. Approaches that could speed up the development of novel anti-
virals would be beneficial for novel anti-HCV drugs and drugs against other 
viral pathogens. 
 
 
4.1.1. Analysis of novel HCV NS3/4A protease inhibitors designed  
using the fragment-based drug design approach (I, unpublished data) 
All currently approved HCV NS3/4A protease inhibitors (and compounds in 
late stages of clinical trials) are based on the structures of modified peptide sub-
strates. Boceprevir and telaprevir are peptidomimetics, and other inhibitors are 
either tripeptide or macrocyclic compounds. Their structures are complex, and 
they have relatively high molecular masses, from ~520 Da (boceprevir) to ~870 
Da (faldaprevir). All of these compounds have a long history of development. 
Here, we tested whether a simpler rational drug design approach can be used to 
develop compounds that target the NS3/4A protease and inhibit HCV replication.  
 
 
4.1.1.1. Fragment-based design, assessment and  
selection of compounds 
Rational design and selection is one approach obtaining new antivirals. Compu-
tational technology, which is based on the fragmentation of chemical com-
pounds, can estimate the activities of new inhibitor candidates. Here, this tech-
nology was applied to generate new potential inhibitors targeting the HCV 
NS3/4A protease. The employed data set consisted of 102 chemical compounds 
that are known to inhibit the HCV NS3/4A protease. The compounds used in 
the calculations included boceprevir (then known as SCH503034), telaprevir 
(VX-950) and the failed drug Ciluprevir (BILN2061), with different modi-
fications (345–350). All of these compounds are relatively large molecules and 
have different possible configurations. Using the Fragment–based Quantitative 
Structure–Activity Relationship (FQSAR) method, these substances were sepa-
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rated into three fragments, resulting in a set of 103 different structural frag-
ments. In silico combination of these fragments and selection using the FQSAR 
approach generated a list that consisted of 20 new potential HCV inhibitors with 
high predicted Log (1/Ki) values.  
The downside of this type of in silico design is that the predicted compounds 
are not typically available; in most cases they simply do not exist. The chemical 
synthesis of novel compounds is costly and time consuming. To circumvent this 
problem, a search of commercially available compound databases was per-
formed to find compounds that are structurally similar to the 20 potential inhibi-
tors found using the FQSAR calculations. This approach is not ideal, as even 
minor changes in the compound structure can alter (or eliminate) its inhibitory 
properties. This search resulted in seven compounds that were selected for fur-
ther experiments (hereafter referred to as compounds 19145, 31356, 24757, 
23330, 233332, 32385, and 32787; I; Supplementary Material 1, Fig. S1).  
 
 
4.1.1.2. Analysis of the cytotoxicity of selected  
NS3/4A protease inhibitor candidates 
The compounds that were selected via rational in silico design were predicted to 
inhibit HCV replication by inhibiting NS3/4A protease activity. To test this 
hypothesis, we decided to use a cell-based assay using the Huh-luc/neo-ET cell 
line (licensed from ReBlikon GmbH). This stable cell line harbours an HCV 
replicon containing the firefly luciferase (Luc) reporter gene to simplify 
measurements of HCV replication (II, Fig. 2A).  
In cell-based assays, the inhibition of virus replication may also result from 
indirect effects of the compounds. Therefore, cytotoxicity is among the first 
properties of any novel antiviral compound to be tested. For this purpose, dif-
ferent cytotoxicity assays have been developed. Most of these assays, such as 
the MTT or WST assays, measure the metabolic activity of cells at the endpoint 
of the analysis. However, HCV replication is also strictly dependent on host cell 
growth; the highest levels of HCV replication (proteins, RNA) are observed in 
actively growing cells, and a sharp decline is observed in resting cells. Most 
likely, this phenomenon occurs because cellular factors that are required for 
HCV RNA replication and/or translation vary in abundance and are limited in 
non-dividing cells (123, 351). Therefore, compounds that cause cytostatic 
effects may also supress HCV replication. Thus, assays that also monitor the 
effects of the tested compounds on cell growth are clearly more adequate. One 
such assay is based on the use of the xCELLigence System RTCA MP Instru-
ment (ACEA Biosciences). This system measures the growth of the cells in a 
real-time setting, and cytostatic effects of compounds can be detected easily. 
For these reasons, all cytotoxicity measurements were performed using this 
system and verified using the MTT assay and visual microscopy observations.  
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All selected compounds were diluted in DMSO and applied to Huh-luc/neo-
ET cells as described in section 3, at final concentrations of 1, 10 and 20 μM. 
Higher concentrations were excluded, as at concentrations of 50 μM or higher 
cell damage was observed visually using microscopy. Using the xCELLigence 
System, it was found that at the 20 μM concentration, only compounds 23330 
and 23332 lacked cytotoxic/cytostatic effects, compounds 32787, 24757 and 
31356 had moderate effects on cell growth, and substances 19145 and 32385 
profoundly inhibited cell growth. At the 10 μM concentration, the cytotoxic 
effects were substantially lower, and at the 1 μM concentration, no cytotoxicity 
was observed (I, Supplementary Material 3 Fig. S1). When the same com-
pounds were analysed using the MTT assay, only relatively mild cytotoxic 
effects were observed, even at the highest (20 µM) concentrations. At this 
concentration, only compounds 24757 and 32385 reduced cell viability by 
≈50%. Interestingly, no cytotoxicity was detected for compound 19145 (Fig. 5). 
This observation contrasted with the findings obtained using the xCELLigence 
System, where this compound exerted clear effects on the cells at both the 10 
μM and 20 μM concentrations (I, Supplementary Material 3, Fig. S1A). One 
possible explanation for this discrepancy is that compound 19145 is not directly 
toxic to the cells but rather has a cytostatic effect. Thus, this analysis confirmed 
that the MTT assay is less sensitive and less informative than the use of the 
xCELLigence System.  
 
Figure 5. Effects of compounds 19145, 31356, 24757, 23330, 23332, 32385, and 32787 
on the viability of Huh7-luc/neo-ET cells. Cell viability was measured using the MTT 
assay. The viability of cells treated with the vehicle control (0.2% DMSO) is taken as 
100%. The results of one (of two) reproducible experiment are shown. 
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4.1.1.3. In silico predicted compounds inhibit  
HCV replication in cell culture 
The quality of in silico prediction depends on the methods used and on the 
amount and quality of the input data. Furthermore, the properties of compounds 
used in biological assays may not correspond to the properties of in silico pre-
dicted hits. The inhibitory properties of compounds may also be reduced due to 
their poor bioavailability. For these reasons, compounds selected using in silico 
approaches often lack the expected properties.  
Compounds were applied to sub-confluent Huh-luc/neo-ET cell cultures at a 
final concentration of 10 μM. The cells were lysed at 24, 48, 96, 120, and 144 h 
post-treatment, and luciferase activity, which is proportional to the copy number 
of HCV RNA in the cells (352), was measured. The obtained luciferase activi-
ties were first normalized to the amount of total protein (measured using the 
Bradford assay), and the obtained values were normalized to the vehicle control 
(taken as 100%). No inhibition of HCV replication was observed at 24 h post-
treatment in any case (Fig. 6). The exception was compound 32385, for which 
the observed inhibition originated from its cytotoxic/cytostatic effects (I, 
Supplementary Material 3 Fig. S1). For most of the compounds, the lack of 
inhibition probably occurred because considerable time is required for the com-
pounds to cause a reduction of HCV mRNA levels and/or because of Fluc is 
relatively stable protein with half life ≈ 3 h. In line with these assumptions, the 
inhibition of HCV replication became apparent at 48 h post-treatment (except 
for compounds 31356 and 23332); at 72 h post-treatment, inhibition was 
observed for all compounds. At the later time points, inhibition either increased 
slightly (23330; 23332, 32787) or remained at the same level as that observed at 
72 h post-treatment (19145, 31356, 24757) (Fig. 6). Thus, at the 10 μM 
concentration, all of the selected compounds were able to inhibit HCV repli-
cation, although for compounds 19145 and 32385, this effect may be indirect 
(caused by cytotoxic/cytostatic side effects of the compound). This emphasizes 
the need for use of the most sensitive method(s) for detection of side effects of 
compounds. Compounds 19145 and 32385 would have been considered to be 
direct HCV inhibitors if only MTT assay (which did not reveal cytotoxicity at 
10 μM concentration (Fig. 5)) had been used. It should also be noted that the 
inhibition of HCV replication (with the exception of cytotoxic compound 
32385) was moderate, being most pronounced for compounds 23330 and 32787 
(Fig. 6). 
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 Figure 6. Time dependence of the inhibition of HCV replication in Huh-luc/neo-ET 
cells treated with the compounds at a final concentration of 10 μM. The cells were lysed 
at the indicated time points; the luciferase activities and total protein contents of the 
lysates were measured. The luciferase activities, which were normalized to the protein 
content, in cells treated with the vehicle control were taken as 100%. The means of 
triplicate experiments are shown with the standard error.  
 
 
Finally, the concentration dependence of HCV replication inhibition was ana-
lysed. Due to the limited amount of available compounds, this experiment was 
performed only once; hence, it is not known if the data presented below are 
reproducible. The cells were lysed at 48 h post-treatment, and the analysis was 
carried out as described above. Compound 23330 inhibited HCV replication at 
the 0.1 μM concentration but not at the 1 μM concentration (Fig. 7). Thus, the 
inhibition observed at the lower concentration was an experimental error. No 
other compound was able to inhibit HCV replication at the 0.1 μM concen-
tration. Instead, some compounds (such as 24757) slightly activated HCV repli-
cation (Fig. 7). Overall, only two compounds demonstrated concentration-de-
pendent inhibition. Compound 32385 inhibited HCV replication by 30% at the 
1 μM concentration. At the 10 μM concentration, replication was reduced by 
nearly 80% (Fig. 7); however, the effect was overshadowed by the observed 
cytotoxicity (I; Supplementary Material 3 Fig. S1). Compound 23332 also 
showed concentration-dependent inhibition and suppressed HCV replication by 
approximately 50% at the 1 μM and 10 μM concentrations. As compound 
23332 was not toxic at these concentrations (I; Supplementary Material 3 Fig. 
S1), this effect likely results from direct anti-HCV activity. It is also possible 
that in this experiment, the full potency of compound 23332 was not revealed, 
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as the antiviral effects of this compound are more prominent at late time points 
(Fig. 6). Compounds 23330, 31356, 24275 and 19145 also inhibited HCV repli-
cation at 10 μM, but no inhibition was observed at lower concentrations. 
 
 
Figure 7. Concentration dependence of HCV replication inhibition. Huh-luc/neo-ET 
cells were treated with the compounds at final concentrations of 0.1 μM, 1 μM or 10 
μM. The cells were lysed at 48 h post-treatment. The luciferase activities and total pro-
tein contents of the lysates were measured. The luciferase activities, which were nor-
malized to the protein content, in cells treated with the vehicle control were taken as 
100%. The experiment was performed only once; hence, no error bars can be shown.  
 
 
Based on the obtained data, we can conclude that compound 23332 (and pos-
sibly some other compounds) can directly inhibit HCV replication. However, 
we lack actual proof that this effect occurs due to the inhibition of NS3/4A pro-
tease activity. It became clear that data from a cell-free protease assay would be 
very important for supporting the data acquired from cell culture experiments. 
Interestingly, most of recent studies dedicated to the development of CHIKV 
protease inhibitors suffer from similar shortcomings (320, 321). It should also 
be concluded that all analysed substances, including compound 23332, were not 
very potent inhibitors. Too few concentrations were tested to enable the reliable 
calculation of an inhibitory concentration 50 (IC50), but it could be estimated 
that the IC50 of compound 23332 is in the low micromolar range. The low 
potency of the hit compounds found in the initial screens is not surprising and 
serves as indication that in silico design should be an iterative process that 
involves multiple rounds of hit compound optimization. However, even if only 
a single compound (of seven) had specific anti-HCV activity, it could be con-
cluded that the discovery rate of hit compounds with some anti-HCV activity 
using the applied approach was relatively high (at least when compared to the 
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screening of chemical libraries that are not pre-selected in silico). It would have 
been interesting to analyse the anti-HCV activities of the structures directly 
generated by the FQSAR process. This information would have been important 
for estimating how much potency was lost (or gained, which is rather unlikely) 
due to the replacement of the predicted inhibitors with structurally similar 
commercially available compounds. 
Finally, this study was the first experience of our research group collabo-
rating with a theoretical chemistry research team. The lessons learned from this 
work were indeed helpful for subsequent joint projects dedicated to the develop-
ment of non-nucleoside inhibitors of HIV-1 reverse transcriptase (Viira et al., 
submitted), for the screening of inhibitors of CHIKV replication (Pohjala et al., 
2011), and for the generation of a unique library of rationally designed inhibi-
tors of the CHIKV nsP2 protease (Das et al., unpublished data).  
 
 
4.1.2. Design and analysis of modified ASOs targeting a highly 
structured coding region of the HCV genome (II) 
ASOs are the most straightforward type of inhibitors, and their design appears 
to be extremely simple. However, in practice, the development of efficient and 
specific ASO inhibitors is much more complicated (see 1.3.3). In the next study, 
numerous aspects of ASO inhibitor development were analysed using the HCV 
genome as a target. 
 
 
4.1.2.1. Selection of target sites for highly efficient ASOs 
The potency of an ASO is largely dependent on the accessibility of its target 
site. Additionally, an ASO must bind to its target with sufficient specificity and 
efficiency, and it must also affect the functions of the targeted RNA.  
The genomic RNA of HCV is highly structured (353) and serves as example 
of RNA that is difficult to target. The true high-order structure of the coding 
region of the HCV genome is not known. In contrast, the HCV 5’ UTR struc-
ture is well characterized, and different ASOs that bind to the IRES or other 
parts of the 5’ UTR have been designed (86, 354). However, the 5’ UTR is only 
a small part (less than 5%) of the whole HCV genome, and this strategy there-
fore omits many potential ASO target sites. 
One obvious approach includes targeting sequences that are conserved 
between different HCV GTs. Another possibility is to target regions of genomes 
that have a certain nucleotide composition (for example, a high C/G content). 
Regions lacking extensive secondary structures could be predicted using mini-
mum free energy calculations. Here, all of these approaches were attempted but 
failed to produce significant results. Therefore, an empirical method was devel-
oped and used for ASO target site selection.  
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We used an RNA interference (RNAi)-guided approach to select ASO target 
sites in the HCV coding region. It was assumed that efficient inhibition of HCV 
replication by certain siRNAs serves as indication of the accessibility of the 
corresponding target site. To ensure the detection of useful target sites, an in-
house algorithm (developed by Andrei Nikonov) was used to design 28 dif-
ferent siRNAs targeting sequences located in the NS3-NS5B coding region of 
HCV GT1b (II, Table 3). These siRNAs (and relevant positive and negative 
control siRNAs) were used to target the replication of the HCV replicon in Huh-
luc/neo-ET cells. As expected, not all siRNAs could inhibit HCV replication 
(II, Fig. 2B), either because their target sites were inaccessible (true negative 
results) or because the siRNAs were not efficient for other reasons (false nega-
tive results). Twelve siRNAs had minimal or no effects on HCV replication (as 
in I, HCV replication was estimated by measuring the luciferase activity pro-
duced by the HCV replicon). The inhibition achieved by fourteen siRNAs was 
considered moderate. From the panel of 28 siRNAs, only siRNA3570 and 
siRNA4676 were capable of supressing HCV replication to a greater extent than 
positive control siRNAs targeting the largely unstructured region encoding the 
luciferase reporter. The target sites of these siRNAs, which were designated as 
sites 3570 and 4676, were subsequently used as binding sites for a set of ASOs. 
 
 
4.1.2.2. 8-oxo-2’-deoxyguanosine (8-oxo-dG) residues affect  
the binding of ASOs to their targets 
Most of the currently used modifications in ASO structures affect the 
oligonucleotide backbone; alternatively bulky and non-natural nucleobase ana-
logues are used. In contrast, 8-oxo-2’-deoxyguanosine (8-oxo-dG) and 5-
hydroxy-2’-deoxycytidine (5-OH-dC) residues contain minimally modified 
nucleobases that do occur naturally (these residues represent products of oxi-
dative DNA damage). Quantum-chemical calculations revealed that both of 
these nucleobases possess two tautomeric forms: major and minor (II, Fig. 1A). 
The properties of these forms are different; the minor tautomeric form mediates 
abnormally strong binding towards the complementary nucleotide (355), while 
the major form of 8-oxo-dG has been shown to bind the complementary 
cytidine more weakly than the non-modified guanosine (356). It was not known 
which tautomeric form of the modified nucleobase (minor or major) has a big-
ger impact on the properties of ASOs containing such modified nucleobases.  
An effective ASO must form a stable duplex with its target sequence. There-
fore, the effect of 8-oxo-dG and 5-OH-dC modifications in ASOs on the ther-
mal stability (melting temperature, Tm) of their duplexes with DNA and RNA 
targets was estimated. The analysis revealed that the incorporation of 8-oxo-dG 
into all-DNA ASOs reduced the Tm of the ASO:DNA and ASO:RNA duplexes. 
Each inserted 8-oxo-dG residue reduced the Tm by 1.6–2.5°C (II, Fig. 1B, 1C). 
Based on these data, one can speculate that under the employed conditions, 8-
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oxo-dG was present in its weakly binding major tautomeric (6,8-diketo) form. 
Interestingly, the incorporation of 5-OH-dC residues did not affect the Tm of 
the ASO:target duplexes (II, Fig. 1B, 1C). 
To analyse the effect of 8-oxo-dG residues on the ASO:RNA duplexes in a 
more detailed manner, the stability of duplexes of ASOs containing LNA 
nucleobases at their termini (LNA/DNA gapmers) with their targets was also 
measured. As expected, the presence of LNA bases in an ASO greatly increased 
the Tm of the ASO:target duplexes. Similar to the case of all-DNA ASOs, the 
8-oxo-dG residues reduced the Tm of the LNA/DNA ASO:target duplexes; the 
reduction was approximately 2–3°C per modified residue (II, Fig. 5A, 5B). It is 
possible that the exact extent of the 8-oxo-dG modification on the Tm of an 
ASO may depend on multiple additional factors, including the overall nucleo-
tide composition, the presence of additional modifications (including modifica-
tions of the oligonucleotide backbone) and the environmental conditions (pH, 
ionic strength of the solution, etc.). However, based on our current findings, it 
could be concluded that weaker binding to their targets is most likely a general 
property of ASOs containing 8-oxo-dG residues. The effect (if any) of the 
minor tautomeric form of 8-oxo-dG residues could not be detected using the 
applied methods. 
Next, the effect of 8-oxo-dG residues on the efficiency of ASO:target duplex 
formation was evaluated. Depending on the conditions, such as temperature, the 
target RNA can have different conformations. As the normal body temperature 
is most relevant for practical use of ASOs, the assay was carried out at 37°C. It 
was found that the incorporation of 8-oxo-dG into all-DNA ASOs clearly 
reduces the efficiency of ASO:target duplex formation. In contrast, no effect of 
such modification on the formation of LNA/DNA gapmer ASO:target duplexes 
was observed (II, Fig. 5C). Thus, the negative impact of 8-oxo-dG residues was 
likely overshadowed by the presence of LNA bases, which ensured strong bind-
ing of an LNA/DNA gapmer ASO to its target. Hence, to obtain inhibitory com-
pounds, 8-oxo-dG modifications should be used in combination with additional 
modification(s) that increase the binding efficiency of the ASO. 
  
 
4.1.2.3. Design of efficient ASO inhibitors 
Due to inefficient binding to their targets and short half-lives in biological 
environments, all-DNA ASOs are poor antisense inhibitors. More potent ASOs 
can be obtained by including different modifications (briefly reviewed in 1.3.3). 
Several such modifications were tested in the early stages of the current study 
(including PTO ASOs). Due to quality problems (briefly discussed in the Mate-
rial and Methods section of II), the obtained results were inconclusive. 
When combining different modifications into a single ASO, several aspects 
should be considered. As 8-oxo-dG residues reduce the Tm of the compound, 
the additional modification(s) should have an opposite effect. The inclusion of 
additional types of nucleobase modifications would likely complicate the inter-
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pretation of the data, and such combinations would complicate the synthesis of 
ASOs. For example, we were never able to obtain ASOs containing both 8-oxo-
dG and 5-OH-dC residues; such compounds were ordered from severeal service 
providers, but ultimately, no company was able to produce them. Thus, the 
modification(s) of the oligonucleotide backbone represents the best choice. It 
should also be mentioned that we do not have a facility that can synthesize 
ASOs or substrates for their synthesis; hence, we were dependent on what was 
available on the market. To our knowledge, the only substrate available (at least 
at the time when the study was initiated) contained 8-oxo-guanosine (or 5-
hydroxy-cytidine) bound to the deoxyribose sugar. Thus, all-LNA (or all-2′-
OMe RNA, all-morpholino or all-PNA) ASOs with 8-oxo-G (or 5-OH-C) modi-
fications were very difficult to obtain, if not completely impossible. Con-
sequently, the included modification must be compatible with standard deoxy-
ribose sugars in the ASO backbone.  
ASOs can inhibit mRNA (virus genome) translation in two different ways: 
via steric blockade of the translation machinery or by activating cellular RNase 
H, which leads to the degradation of target RNA. To act as a steric inhibitor, an 
ASO must bind an element required for the initiation of translation. Both 
selected target sites (3570 and 4676) are located in the coding region of the 
HCV genome. Hence, in our case, the modified ASO, in order to be efficient, 
should be able to trigger the degradation of the targeted RNA.  
LNA bases, when incorporated into an ASO, enhance its stability and 
increase ASO:target duplex formation (86, 357). However, all-LNA ASOs and 
LNA/DNA mixomer ASOs (oligonucleotides in which DNA bases are inter-
spaced by LNA bases) cannot activate RNase H (II, Fig. 6B, 6C) because 
RNase H requires the presence of an uninterrupted RNA:DNA duplex no less 
than 6 bp in length (86). Thus, LNA/DNA gapmers, which fulfil this require-
ment, represent the best choice. Given the availability of substrates for oligonu-
cleotide synthesis, all 8-oxo-G or 5-OH-C modifications were located in the 
central (DNA) parts of these ASOs (II, Table 1). 
 
 
4.1.2.4. 8-oxo-dG residues have a small effect  
on the antiviral potency of LNA/DNA gapmer ASOs 
To analyse the effect of 8-oxo-dG residues on the inhibitory potency of ASOs, 
such modifications were incorporated into compounds targeting site 4676 in the 
HCV replicon RNA. As the central part of this site contains three cytosine resi-
dues, the ASOs were designed to contain three 8-oxo-dG residues. All obtained 
ASOs (II, Table 1) were evaluated for the ability to supress HCV replication in 
Huh-luc/neo-ET cells. 
Notably, these experiments were considerably more complicated than the 
experiments described in publication I. This was because unlike low molecular 
mass compounds, ASOs were unable to enter Huh-luc/neo-ET cells on their 
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own and required a transfection procedure. Many different transfection reagents 
are available, but they are all designed to facilitate the delivery of commonly 
used types of nucleic acids: plasmid DNAs, RNA transcripts or siRNAs. Simi-
larly, there are also many different transfection protocols, but none of them was 
specifically developed for the types of compounds used in this study. To over-
come these issues, seven different transfection reagents and a number of proto-
cols were tested. We concluded that with the existing reagents, it was impos-
sible to obtain good transfection efficiencies without causing substantial cell 
damage. As a compromise, a method (Lipofectamine 2000 and reverse trans-
fection protocol) that resulted in transfection of approximately 75% of the cells 
and caused minimal (though in some cases, still detectable) damage to the cells 
was selected. Thus, although we did our best to take into account the cytotoxic 
effects of the ASO-transfection reagent combinations, it is likely that cytotoxity, 
not necessarily caused by ASO itself but originating from combination of mul-
tiple factors, still had some impact on the results of some experiments. 
First, an all-DNA ASO (D4676) was confirmed to be a very poor inhibitor of 
HCV replication (II, Fig. 4A). In contrast, the corresponding siRNA (4676) was 
a very potent inhibitor, with an effective concentration 50 (EC50) of 0.13 nM 
(II, Table 4). Second, an LNA gapmer lacking 8-oxo-dG residues (LD4676) 
was also an efficient inhibitor of HCV replication and had an EC50 of 5.5 nM 
(II, Table 4). Interestingly, even when applied at a 100 nM concentration (>18-
fold higher than the EC50), the compound still failed to cause complete inhi-
bition of HCV replication. Inhibition did not exceed 60% and never reached the 
same level observed in siRNA-treated cells (II, Fig. 4A). Third, the introduction 
of 8-oxo-dG residues into the LNA gapmer (LDM4676) enabled the ASO to 
supress HCV replication nearly completely in transfected cells. Thus, at the 100 
nM concentration, LDM4676 inhibited HCV replication by approximately 73%, 
which was similar to the rate achieved with siRNA (II, Fig. 4A). Note that 
~75% inhibition corresponds to complete inhibition, as in these experiments 
~25% of the cells remained un-transfected, and HCV replication in these cells 
was presumably unaffected. Regardless of the more pronounced inhibition, the 
EC50 for LDM4676 was 7.1 nM, which was slightly higher than the EC50 of 
LD4674 (II, Table 4). Fourth, an interesting phenomenon was observed for the 
inverted control ASOs. The LNA/DNA gapmer LD4676inv powerfully acti-
vated HCV replication, and the presence of 8-oxo-dG residues (LDM4676inv) 
reduced this effect (II, Fig. 4C). The origin of the unexpected activation of 
HCV replication remains unknown, but it could be speculated that LD4676inv 
interacted with some non-target cellular RNAs and that this interaction some-
how boosted HCV replication. If this theory is correct, the reduced off-target 
effects of LDM4676inv likely result from its reduced Tm.  
Taken together, these data indicate that the presence of 8-oxo-dG residues in 
the LNA/DNA gapmer ASO led to changes in its properties. Generally, 
LDM4676 performed better than its counterpart LD4676. This finding led us to 
conclude that ASOs with 8-oxo-dG residues were better inhibitors than could be 
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expected based on their Tm values (II; Fig. 5B), leading to the hypothesis that 
Tm is likely not the only property of an ASO that is affected by the presence of 
8-oxo-dG residues. 
 
 
4.1.2.5. 8-oxo-dG modifications impact multiple properties  
of ASOs that can affect their antiviral potency 
In addition to Tm (the binding efficiency to the target and the stability of the 
formed ASO:target duplex), the antiviral effect of an ASO also depends on its 
ability to activate RNase H-mediated target RNA degradation and on the sta-
bility of the ASO in biological environments.  
To analyse the effect of 8-oxo-dG residues on RNase H-mediated target 
degradation, two different experiments were performed. In the first experiment, 
ASO:RNA duplexes were pre-made, purified and treated with bacterial RNase 
H (human RNase H enzymes are not commercially available). Consistent with 
previous studies (86), we observed that duplexes with an LNA mixomer ASO 
were completely resistant to RNase H (II, Fig. 6B, 6C). In contrast, the RNA 
strands of duplexes made using D4676, DM4676, LD4676 and LDM4676 were 
degraded by RNase H. The presence of 8-oxo-dG residues had no detectable 
effect on the speed or efficiency of duplex degradation (II, Fig. 6C). However, 
differences in the reaction products were observed. For duplexes containing 
D4676 (or LD4676), only one main labelled cleavage product was observed. At 
the same time, the degradation of duplexes containing DM4676 (or LDM4676) 
resulted in two cleavage products (II, Fig. 6B). Thus, the incorporation of 8-
oxo-dG residues into an ASO affected the positions of the bonds in the target 
RNA that were cleaved by RNase H. Another interesting observation was that 
duplexes that were prepared using LNA/DNA gapmer ASOs were degraded 
more efficiently than duplexes containing all-DNA ASOs. The initial speed of 
degradation was similar, but for all-DNA ASO duplexes, the reaction plateaued 
after 0.5 min, and 20–30% of duplexes were left uncleaved. In the case of 
LNA/DNA gapmer ASO duplexes, the reaction continued for up to 5 min, and 
only 10% of the substrate was left uncleaved (II, Fig. 6B, 6C).  
RNase H-mediated cleavage in living cells requires both duplex formation 
and subsequent duplex cleavage. Duplex formation can be affected by the 
sequences surrounding the target site and/or by the high-order structure of the 
targeted RNA. To model these conditions, the experiment was also performed 
using a 3131 nt-long fragment of HCV RNA as a target. We found that the 
presence of LD4676 and LDM4676 in the reaction mixture triggered rapid 
RNase H-mediated degradation of the targeted RNA. The differences between 
the compounds were very small; in both cases, after 60 min, no substrate was 
left (II, Fig. 6D). Compared to the LNA/DNA gapmers, D4676 and DM4676 
triggered slower RNase H-mediated target RNA degradation. Furthermore, in 
this regard, DM4676 was clearly less efficient than D4676 (II, Fig. 6D). Com-
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bined with the data obtained from previous experiments, it can be concluded 
that the degradation of the targeted RNA correlates with the speed and effi-
ciency of ASO:target RNA duplex formation (II, Fig. 5C) and may be further 
affected by the more efficient degradation of duplexes containing LNA/DNA 
gapmers (II, Fig. 6B, 6C). Duplex formation itself depends on the presence of 
8-oxo-dG residues, as these residues reduce the Tm of the ASO:RNA duplexes 
(II, Fig. 5C). The observed effect of nucleobase modification is more prominent 
in the context of all-DNA ASOs, as their Tm values are lower than those of 
LNA/DNA gapmers of the same sequence (II, Fig. 5B).  
Another property of an ASO that affects its antiviral potency is its stability in 
biological environments. The classical approach to increasing the stability of an 
ASO is the introduction of PTO modifications into ASO backbone, but the 
introduction of LNA bases is also known to increase ASO stability. Miravirsen, 
which is an inhibitor of mir-122, contains a combination of these modifications 
and has a serum half-life of more than one week (354). As ASOs are injectable 
drugs, the long half-life is especially important. As it was not known how 8-
oxo-dG residues affect the stability of ASOs, the D4676, DM4676, LD4676 and 
LDM4676 were labelled and incubated in human serum. Consistent with previ-
ous studies, we observed that LNA/DNA gapmers have a much longer (>10-
fold) serum half-life than all-DNA ASOs (II, Fig. 7). Importantly, it was found 
that three 8-oxo-dG residues significantly increased the half-lives of both all-
DNA (from ~8 min to ~15 min) and LNA/DNA gapmer (from ~90 min to ~130 
min) ASOs (II, Fig. 7). Thus, the observed high antiviral activity of LDM4676 
(II, Fig. 4A) could be partly explained by the increased stability of the com-
pound. However, it is also clear that the increased stability of a compound in an 
in vitro assay does not necessarily indicate its superior stability under much 
more complex in vivo conditions. It is therefore important to further assess the 
effect of 8-oxo-dG modification on ASO stability in vivo.  
 
 
4.1.2.6. Inhibitory properties of ASOs are affected by mutations  
in the target site 
The efficacy of nucleic acid based inhibitors (siRNAs, ASOs) depends on the 
match between their sequence and the target site. In this regard, siRNAs are 
especially sensitive; a single nucleotide mismatch can completely destroy the 
efficacy of the inhibitor. In the case of ASOs, there is usually no demand for a 
perfect match; however, ASOs also lose potency if they cannot bind efficiently 
to the target. This aspect is especially important to take into account when tar-
geting viral genomes. First, viral genomes have a natural variation of sequences. 
HCV, which has multiple GTs, is a prime example of such a virus. The target 
site 4676 (selected on the basis of the GT1b Con1 sequence) is conserved 
(although it may still contain a single mismatch) in GT1b. However, in GT1a 
viruses, up to three nucleotide differences could be present in this region, and in 
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other GTs, up to seven nucleotide differences could be present. Second, RNA 
viruses respond to antiviral treatment by developing resistance. Thus, it was 
important to verify the sensitivity of the modified LNA/DNA gapmer ASOs to 
changes in their target sites. 
Mutations introduced into the coding region may hamper HCV replication 
and/or be reverted. To eliminate the possibility of such unwanted effects, we 
searched the literature for mutations located in the 4676 or 3570 target sites that 
were reported to have no (or minimal) effect on virus replication. No such 
mutation was described for site 4676. However, site 3570 contains a codon that 
is changed from Thr to Ala in HCV mutants that are resistant to first-generation 
protease inhibitors. In the Con1 sequence, this mutation (3579 A→G) is located 
conveniently in the middle of the 3570 target site (II, Fig. 3A). To test the 
mutation’s effect on the efficiency of the modified ASO, a new compound 
(LDM3570) that contained three 5-OH-dC residues and a cell line designated as 
Huh-luc/neo-ET-3570mut were created. Using these tools, we found that this 
mismatch reduced the inhibitory effect of LDM3570 by ~20% but had no effect 
on the efficacy of LDM4676 targeting a different site (II, Fig. 3B). As expected, 
the impact of the same mutation on the efficacy of an siRNA targeting the 3570 
site was much more prominent (nearly 10-fold) (II, Fig. 3B). There is no doubt 
that 5-OH-dC residues are not the perfect control for 8-oxo-dG residues, as the 
effects of 5-OH-dC residues on the Tm of the compound are different from the 
effects of 8-oxo-dG residues (II, Fig. 1C). Nevertheless, it can be concluded 
that the efficacy of a modified ASO with naturally occurring nucleobases is 
affected by mutations in its target site but to a lesser extent than the efficacy of 
the corresponding siRNAs.  
 
 
4.1.2.7. Can 8-oxo-dG modifications be used for  
the development of improved ASO drugs?  
The ASO project was large and very resource- and time-consuming (only a 
fraction of the total data is presented here and in publication II). At its end, 
many questions remained. One of those questions concerns the effects of 8-oxo-
dG modifications in the in vivo system. In vitro analysed ASOs are active (II, 
Fig. 4A) and possess enhanced stability (II, Fig. 7); these properties are attrac-
tive. The intrinsic weakness of all ASOs is delivery. In in vivo systems, this 
issue becomes even more critical than in cell culture assays. The liver is 
actually the only easy in vivo target, as ONs typically end up in this organ (354, 
358–360). For all other targets, specific vehicles are needed for specific delivery 
and cell membrane penetration. Despite some progress, the targeting of dif-
ferent organs remains largely unsolved. Therefore, different ASOs are primarily 
attractive for the treatment of liver diseases.  
The progress made concerning therapies for HCV infection has been remark-
able (see 1.4.5; 1.4.6). Thus, a new drug (or treatment) must not only be effi-
15
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cient but also have some competitive advantages over the current treatments. 
ASOs are likely to remain injectable drugs; thus, ASOs will have some serious 
disadvantages compared to oral drugs. Therefore, the issue of stability (as the 
stability of drug correlates with the frequency with which the drug should be 
injected) could be the most important issue. In this regard, compounds with 8-
oxo-dG residues are quite attractive (II, Fig. 7). Another key feature for the 
successful treatment of viruses (including HCV) is the resistance barrier. Theo-
retically, pre-existing sequence variation should not be a problem, as the 
sequence of an ASO can be easily adjusted to match any target sequence. From 
a practical point of view, this issue highlights the need to develop a family of 
compounds rather than a single compound. That strategy will almost certainly 
be associated with greatly increased costs and will thus be unlikely to be practi-
cal. Rapidly acquired resistance is another problem; modified ASOs are sensi-
tive (although to a much lesser extent than siRNAs) to mutations in their target 
sites (II, Fig. 3B). Thus, a combination of drugs with different targets and/or 
with different mechanisms of action is clearly needed. ASOs could be combined 
with low molecular mass drugs, such as inhibitors of the NS3/4A protease. This 
combination could result in the inhibition of HCV replication (effect of the 
NS3/4A inhibitor) and the destruction of the targeted RNA genome (effect of 
the ASO). As one possibility, a novel ASO inhibitor targeting the HCV genome 
can be combined with another ASO-based drug candidate: the mir-122 inhibitor 
miravirsen. These compounds are chemically similar and could be delivered 
together; however, they have completely different mechanisms of action and 
can thus act in a synergistic manner. Taking into account all of the problems 
associated with targeting HCV RNA, the novel modified ASOs could be 
applied to other targets with better prospects. For instance, the sequences of 
cellular targets (such as mRNAs that are over-expressed in cancer cells) are 
more conserved and do not change nearly as quickly as viral genomes. Clearly, 
a number of issues must be addressed (delivery among them), but the modi-
fications themselves (at least the use of 8-oxo-dG nucleobases) seem to hold 
promise.  
 
 
4.2. Development of an attenuated CHIKV vaccine and 
analysis of the molecular basis of attenuation 
A general description of antiviral vaccines and recent progress in the develop-
ment of a vaccine for the prevention of CHIKV infection are presented above 
(1.2 and 1.5.5). Our research group has been actively involved in multinational 
efforts to develop a novel and efficacious vaccine for CHIKV. For this purpose, 
over 20 different vaccine candidates were constructed; of these candidates, 10 
were tested in a mouse model (334, 336, 342, 361) and three were tested in a 
non-human primate model (Roques et al., submitted manuscript). The con-
struction and analysis of such a large panel of vaccine candidates served the 
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simple and clear aim of producing vaccine candidates that have a realistic 
chance of being tested clinically and becoming licensed for clinical use. To 
have such a chance, we proposed that a vaccine candidate should be genetically 
stable, safe to use (with no pathology), effective after a single immunization, 
able to provide long-lasting protective immunity and easy to produce. It is rela-
tively easy to meet some or even most of these requirements, but it is not easy 
to meet all of them at once. To our knowledge, we succeeded, and our vaccine 
candidate (based on data obtained from a 1.5-year long non-human primate 
study) meets all of these criteria. Our candidate also entered clinical trials in 
2015 (due to the agreement between the University of Tartu and the company 
carrying out trials, the name of the company cannot be disclosed at this stage). 
To our knowledge, our vaccine is the fifth candidate CHIKV vaccine that has 
reached clinical trials.  
The unravelling of the real effects responsible for the attenuation of this vac-
cine virus represents a topic of ongoing studies. As all of these studies involved 
a number of researchers from different laboratories, I will focus only on the 
parts of the corresponding studies in which I actively participated. 
 
  
4.2.1. Deletions in the nsP3 HVD or the 6k region attenuate  
CHIKV replication and generate vaccine candidates that  
elicit protective immune responses in mice (III) 
The main approach used for the development of our set of CHIKV vaccine 
candidates was rational design. We attempted to introduce mutations that pre-
sumably cause serious defects in virus infection in vivo and are also difficult for 
the virus to revert. Large deletions introduced into the reginons encoding viral 
proteins were considered to be the most suitable mutations for this purpose. 
However, for CHIKV, no deletion of this type has been studied. Therefore, we 
obtained an advantage from previous studies of SFV. For SFV, two deletions of 
a similar size (approximately 150 nucleotides) have been shown to have rela-
tively mild effects on the general replication of the virus in cell culture but in 
animal models these deletions restrict virus-induced pathology. The first of 
these deletions removed the N-terminal part of the HVD of nsP3, which con-
tains phosphorylation sites (362). The second deletion removed the entire region 
encoding the 6K protein (363) and also prevented the expression of the TF pro-
tein (although the existence of TF protein was not known at the time when the 
original study was performed).  
These deletions were introduced into the CHIKV genome (ECSA genotype, 
isolate LR2006-OPY1). A mutant harbouring a deletion of the 6K region (desig-
nated as CHIKVΔ6K; III, Fig. 1A) was easy to design. In contrast, the deletion at 
the beginning of the nsP3 HVD was harder to design, as the corresponding 
regions of SFV and CHIKV have no sequence similarity. To overcome this ob-
stacle, a set of 5 viruses, which harboured deletions of different sizes, was con-
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structed and analysed in cell culture. All of these viruses were viable, and no 
notable differences were observed between them. The largest deletion (named 
deletion 5) substituted 62 aa residues from nsP3 (residues 1656 to 1717 of the 
P1234 polyprotein) with a short linker (sequence AYRAAAG). This virus, which 
was designated as CHIKVΔ5nsP3 (III, Fig. 1A), was selected for subsequent 
experiments. CHIKV carrying both deletions (CHIKVΔ5nsP3+Δ6K) was also 
constructed and tested in cell culture. This virus was strongly attenuated and 
was therefore not used as a vaccine candidate (our unpublished data). In con-
trast, both CHIKVΔ5nsP3 and CHIKVΔ6K exhibited only somewhat reduced 
titres (1.2×107 and 1.7×107 pfu/ml, respectively; 4.4×108 pfu/ml for wild-type 
CHIKV) and produced slightly smaller plaques than wild-type CHIKV (III, 
Fig. 1B).  
With all attenuated vaccine candidates, it is essential to demonstrate that the 
attenuated phenotype is maintained (i.e., the attenuated virus is genetically sta-
ble). As the ultimate aim of the study was to produce a vaccine candidate suit-
able for use in humans, experimental proof of its genetic stability over number 
of passages was mandatory. For this purpose, both CHIKVΔ5nsP3 and 
CHIKVΔ6K were passaged in Vero cells at a low multiplicity of infection (0.01 
pfu/cell); five passages were made for CHIKVΔ6K, and CHIKVΔ5nsP3 was 
passaged ten times (five passages were reported in III, five more passages were 
made later). For each passage, the titres of CHIKVΔ5nsP3 and CHIKVΔ6K 
were determined, and the plaque morphology was observed. No changes in 
plaque sizes (which stayed small) were observed, and the end titres of different 
stocks were similar to these of the P0 stocks. Thus, no change in phenotype was 
observed. In addition, genomic RNA was isolated from the P5 and P10 virus 
stocks, and the regions harbouring the deletions were RT-PCR-amplified and 
sequenced. This analysis confirmed that the originally introduced deletions 
were maintained in all analysed stocks. No reversions of deletions or changes in 
the aa sequences of the regions flanking the deletion were detected.  
As the vaccine candidates were found to be genetically stable, they were 
next assayed for the ability to elicit an immune response. Both CHIKVΔ5nsP3 
and CHIKVΔ6K produced some foot swelling in immunized mice; low-titre 
viremia was also observed for CHIKVΔ5nsP3 but not for the CHIKVΔ6K 
vaccine candidate (III, Fig. 3). Both vaccine candidates elicited high levels of 
humoral and cellular immune responses, with CHIKVΔ5nsP3 being more 
efficient (III, Fig. 4). That difference was also maintained (although the 
difference was not statistically significant) in the case of homologous prime-
boost immunization (III, Fig. 7B). Upon challenge with wild-type CHIKV, all 
mice that were immunized with CHIKVΔ5nsP3 were protected against viremia 
and had minimal foot swelling. Viremia was detected in one mouse immunized 
with DNA-launched CHIKVΔ6K, and animals who received that vaccine 
candidate also had somewhat more pronounced foot swelling (III, Fig. 5). 
These data clearly demonstrate that both vaccine candidates were attenuated and 
could provide excellent protection against CHIKV infection. 
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Subsequent studies ((336); Roques et al., submitted manuscript) confirmed 
that CHIKVΔ5nsP3 was the most efficient vaccine candidate, even when 
compared to other tested candidates (including recombinant MVA, different 
DNA vaccines and recombinant proteins with adjuvants). Experiments using 
cynomolgus macaques, which represent a much more relevant model of CHIKV 
infection than mice (364), ultimately demonstrated that CHIKVΔ5nsP3 is 
attenuated in non-human primates and does not produce detectable symptoms. 
Most importantly, single immunization was sufficient to induce a high titre of 
neutralizing antibodies against CHIKV of the ECSA or Asian genotypes, and 
this response lasted for the entire observation period (~1 year). All immunized 
monkeys were completely protected against CHIKV challenge. Based on these 
data, a commercial company took over the vaccine development and initiated 
clinical trials of the CHIKVΔ5nsP3 vaccine candidate. 
 
 
4.2.2. Functional differences in the N-terminal part of the HVD  
of nsP3 in SFV and CHIKV (IV and unpublished data) 
Although new information about the functions of the nsP3 of alphaviruses is 
gradually emerging, the protein remains largely mysterious. Its N-terminal two-
thirds is well conserved among alphaviruses and is folded into two structured 
domains (365), suggesting the existence of yet unknown enzymatic function(s). 
In contrast, the C-terminal HVD is intrinsically unstructured and mediates dif-
ferent virus-host interactions. The first known property of this region is the 
phosphorylation of Ser/Thr residues (366, 367). In the case of SFV, the phos-
phorylated region has been mapped to the N-terminal part of the HVD (368). It 
has been assumed, although never experimentally demonstrated, that the analo-
gously located region of the nsP3 of CHIKV is similarly modified. The HVD is 
also tolerant to different deletions and marker protein insertions (268, 278, 369–
371). Among other modifications, the deletion of the entire phosphorylation 
region (50 aa residues) is well tolerated in SFV. Viruses with such a deletion 
(designated SFVdel50) replicate to a high titre but are avirulent in mice (278). 
As described in 4.2.1, a similarly located region in the nsP3 of CHIKV also 
tolerates various deletions; even the removal of the whole 62 aa residue region 
does not prevent the virus (CHIKVΔ5nsP3) from growing to high titres. These 
similarities led to the logical, but erroneous, assumption that these analogously 
positioned regions of CHIKV and SFV nsP3 are functionally similar. 
Many researchers, including members of our group, have observed con-
sistent differences in the location of replication complexes in SFV and CHIKV 
in infected cells. In both cases, the replicase complexes are initially formed on 
the plasma membrane and subsequently internalized via the phosphati-
dylinositol-3-kinase (PI3K)-Akt signalling pathway using microtubules and the 
actin cytoskeleton (305). During the late stage of infection, SFV replication 
complexes are localized in large perinuclear vesicles (CPV-I), while vesicles 
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containing CHIKV replicase complexes are generally smaller and stay in close 
proximity to the plasma membrane (IV, compare Fig. 6A and 8E). Our col-
leagues observed that in contrast to wild-type SFV, SFVdel50 does not inter-
nalize its replication complexes (IV, Fig. 4A) and is unable to cause the hyper-
activation of the cellular PI3K-Akt-mTOR pathway (IV, Fig. 4B, 4C). More-
over, there was a perfect correlation between the ability of SFV and its mutant 
forms to cause hyper-activation of the PI3K-Akt-mTOR pathway and to inter-
nalize replication complexes (IV, Fig. 7). This correlation was emphasized by 
the finding that CHIKV replication complexes are located in the cell periphery 
and that similar to SFVdel50, CHIKV is also unable to hyper-activate the PI3K-
Akt-mTOR pathway (IV, Fig. 8). Swapping the HDV regions of SFV and 
CHIKV clearly indicated that this region was solely responsible for these 
phenotypic differences between SFV and CHIKV (IV, Fig. 10). These findings 
also confirmed that virus-cell interactions, which are mediated by different 
alphaviral nsP3 HVDs, result in different phenotypes.  
During this study, we hypothesized that the determinant(s) needed for the 
hyper-activation of the PI3K-Akt-mTOR pathway are located inside the region 
of SFV nsP3 that is covered by the del50 deletion. If so, the swapping of this 
region with the corresponding region from CHIKV should result in chimeric 
nsP3 proteins with switched properties. The replacement of 50 aa residues of 
SFV nsP3 with 62 aa residues from nsP3 of CHIKV (thus, swapping the regions 
affected by del50 in SFV and by Δ5nsP3 in CHIKV) indeed resulted in a chi-
meric protein (SFV/CHIKV5-nsP3) that was unable to hyper-activate the PI3K-
Akt-mTOR pathway (IV; Fig. 9D). The reciprocal swap resulted in the 
CHIKV/SFV50-nsP3 chimeric protein, which was also unable to hyper-activate 
the PI3K-Ak-mTOR pathway (IV; Fig. 9E). Thus, the swapping of these re-
gions was not sufficient (unlike the swapping of the full HVDs) to transfer the 
ability to hyper-activate the PI3K-Akt-mTOR pathway from SFV nsP3 to the 
nsP3 of CHIKV. This finding indicates that the determinants required for the 
hyper-activation of the PI3K-Akt-mTOR pathway are not fully localized within 
the 50 aa region of SFV nsP3 HVD and probably include also some sequences 
localized between aa residues 368 and 408 of the nsP3 of SFV (e.g., between 
the regions affected by the del50 and delP deletions; IV; Fig. 4A).  
The most surprising results were obtained when such swapping was per-
formed in the context of infectious cDNA clones of SFV and CHIKV. First, the 
replacement of the 50 aa region of the nsP3 of SFV with 62 aa residues from the 
nsP3 of CHIKV was poorly tolerated. The infectivity of the obtained construct 
(designated as SFV/CHIKV50) was reduced (compared to the infectivity of the 
wild-type SFV construct) by approximately 100-fold. The reciprocal swap had 
an even more drastic effect: the infectivity of the obtained CHIKV/SFV50 con-
struct was reduced (compared to the infectivity of the wild-type CHIKV con-
struct) by approximately 10,000-fold. These data unequivocally demonstrated 
that the functions of similarly located regions of the nsP3 proteins from SFV 
and CHIKV are drastically different. Furthermore, these functions are clearly 
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incompatible; the deletions of these regions were well tolerated by both SFV 
and CHIKV, but the swapping of these regions was not. The simple conclusion 
is that the molecular basis of the attenuation of CHIKVΔ5nsP3 is most likely 
different from that of SFVdel50.  
The effect caused by this swapping cannot originate from some defect in 
virus-host interactions. Previous studies in our laboratory showed that a 10,000-
fold reduction in the infectivity of recombinant alphaviruses typically originates 
from a severe defect in genome replication (269, 290, 371–373). Effects of this 
magnitude may be caused by a defect in some essential enzymatic activity of 
the ns protein or by a severe defect in interactions between ns proteins, pre-
venting correct replication complex formation. As the swapped region is struc-
turally disordered, the second possibility is far more likely. If a construct har-
bouring such a mutation is capable of producing viable progeny, this scenario is 
always associated either with the reversion of the introduced mutation or with 
the selection of compensatory (second-site) mutations. As the swapping cannot 
be reverted (too many changes are required), a search for potential adaptive 
mutations in viruses rescued from the CHIKV/SFV50 construct was performed. 
In total, the genomes of ten progeny viruses were analysed by sequencing. In 
seven cases, a methionine-to-isoleucine mutation was detected in the ZBD of 
nsP3 (position 1552 in P1234). In the rest of the viruses, an asparagine-to-
isoleucine mutation located in the C-terminal region of nsP2 (position 1318 in 
P1234) was detected. We found that the introduction of either of these muta-
tions back into the CHIKV/SFV50 construct increased its infectivity nearly 
10,000-fold (to a level similar to that of the wild-type CHIKV construct). This 
result clearly demonstrates that these mutations are true compensatory changes 
and not random mutations. The ability of viruses harbouring compensatory 
changes to hyper-activate the PI3K-Akt-mTOR pathway was not analysed, as 
we had already shown that viral progeny rescued from CHIKV/SFV50 lack this 
ability (IV; Fig. 9B). The rescue of the infectivity of CHIKV/SFV50 by a muta-
tion located in the ZBD of nsP3 indicates that for some crucial viral function(s), 
the synchronized action of ZBD and the HVD of nsP3 is required. This finding 
also indicates that there is likely a physical interaction between these two 
domains, although it is unclear whether this interaction occurs within one mole-
cule or as an intermolecular interaction. The compensatory effect of a mutation 
in the C-terminal domain of nsP2 serves as a strong indication that at some 
point of infection, this region acts cooperatively with the nsP3 HVD. It was 
previously shown that the interaction of nsP2 with the C-terminus of the macro-
domain is crucial for the cleavage of the 2/3 site in P1234 (371). Combined, 
these findings emphasize that several functions that are essential for alphavirus 
replication are jointly performed by these two proteins. Clearly, to provide 
proof for any of these (or other) hypotheses, specific studies are needed. 
Furthermore, it appears that such studies may also reveal the true molecular 
basis of the attenuation of the CHIKVΔ5nsP3 vaccine candidate. 
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CONCLUSIONS 
The common aim of the studies presented in this thesis was to develop new 
approaches for targeting the medically important viruses HCV and CHIKV. 
HCV is primarily associated with chronic disease; hence, we focused on the 
development of potential therapeutics - antiviral compounds. CHIKV is asso-
ciated with acute disease (which could result in chronic symptoms); hence, we 
focused on the development and testing of rationally designed candidates for a 
preventive CHIKV vaccine. All of these studies were carried out as collabo-
rative projects between different laboratories and/or experts in different areas 
(quantum-chemistry, oligonucleotide chemistry, immunology, and animal stud-
ies, among others). The main conclusions from these studies are as follows: 
- The new FQSAR method-based approach allowed for the rapid prediction of 
hit compounds targeting the NS3/4A protease of HCV. This approach can, at 
least theoretically, also be applied to other targets. The main obstacle asso-
ciated with this approach is the difficulty of obtaining hit compounds pre-
dicted by FQSAR. The replacement of these compounds with structurally 
similar and commercially available compounds increases the possibility of 
false negative results. In our case, of seven compounds obtained using these 
approaches, only two were non-cytotoxic. Therefore, although all seven 
compounds analysed in this project displayed some anti-HCV properties, 
only the effect caused by the non-cytotoxic compound 23332 can be con-
sidered direct.  
- RNAi-guided selection was successfully used to reveal two potent ASO tar-
get sequences in the highly structured HCV coding region. A novel tech-
nology – the incorporation of naturally occurring minimally modified 
nucleobases into ASOs – was evaluated using ASOs that bind to these tar-
gets. Modified compounds containing 8-oxo-dG residues were capable of 
triggering the RNase H-mediated degradation of their RNA targets and had 
enhanced stability in biological environments. At the same time, these com-
pounds had reduced melting temperatures and an impaired ability to form 
duplexes with their target RNA. The latter effect was largely compensated 
by the introduction of LNA bases into the ASOs. Combined, these 
approaches led to the development of ASO compounds with high antiviral 
activity. However, these inhibitors were sensitive to mutations located in 
their target sites and also had cytotoxic side effects. It could be concluded 
that technology based on the use of novel modified ONs is promising but is 
likely to be more suitable for targeting the unwanted expression of cellular 
genes (such as oncogenes) than for targeting rapidly mutating virus 
genomes. 
- Rational design was used to develop a number of promising anti-CHIKV 
vaccine candidates. Two of those candidates were viruses that were attenu-
ated by deletions of large (≥150 nucleotides) parts of coding regions. These 
viruses (CHIKVΔ5nsP3 and CHIKVΔ6K) were found to have a stable 
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attenuated phenotype, and the introduced changes were maintained during 
serial passages. Of all of the studied vaccine candidates, CHIKVΔ5nsP3 was 
the most potent; a single immunization provided full and long-lasting protec-
tion of all vaccinated animals. The design of this vaccine candidate was 
based on that of a previously studied SFV mutant. Surprisingly, it was found 
that the functions of the region affected by the deletion are different in SFV 
and CHIKV. In the case of SFV, this region, which is located in the N-termi-
nal part of the HVD of nsP3, acts as part of a sequence element responsible 
for the hyper-activation of the PI3K-Akt-mTOR pathway. CHIKV, in con-
trast, lacks this property, and the corresponding region in nsP3 apparently 
has other function(s). It was found that although these regions of SFV and 
CHIKV are dispensable for virus replication, they are not interchangeable. 
The analysis of virus progeny rescued from constructs harbouring such 
swaps in the nsP3 region revealed that the region removed from the 
CHIKVΔ5nsP3 vaccine candidate is apparently involved in interactions with 
another domain of nsP3 and with the C-terminal region of nsP2. These 
findings provide a platform for further analysis of the biological causes of 
the attenuation of the CHIKVΔ5nsP3 vaccine candidate. 
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SUMMARY IN ESTONIAN 
Hepatiit C viiruse ja Chikungunya viiruse vastased lähenemised 
Tänapäeval on võimalik ennast erinevate viiruste vastu vaktsineerida ning ka 
viirushaiguste ravi on muutunud oluliselt tõhusamaks. Samas leidub endiselt 
meditsiiniliselt tähtsaid viiruseid, mille vastu puudub vaktsiin ja/või mille 
põhjustatud haigustele pole siiani adekvaatset ravi. Viiruste mitmekesisus, 
nende keerukas elutsükkel ning sellised omadused nagu kiire muteerumine, 
efektiivne replikatsioon, rekombinatsioon ning varjumine immuunsüsteemi eest 
on vaid mõned aspektid, mis raskendavad antiviraalsete ühendite ja vaktsiinide 
väljatöötamist.  
Hepatiit C viirus (HCV) on maksapatoloogiate (fibroos, tsirroos, maksa-
kasvajad) üheks levinumaks tekkepõhjuseks. Hinnanguliselt on selle viirusega 
krooniliselt nakatunud ~3% inimkonnast. Kroonilise HCV infektsiooni raviks 
kasutatakse uudseid HCV vastaseid inhibiitoreid, mis võimaldavad kasutada 
interferoonivaba raviskeemi. Selline ravi omab kuni 99%-st efektiivsust kuid on 
kallis, selle efektiivsus on sõltuv viiruse genotüübist ning juba väljaarenenud 
patoloogiast; lisaks võib ravi põhjustada tõsiseid kõrvalmõjusid. Seetõttu on 
uute HCV vastaste ühendite arendamine endiselt oluline.  
Antud töö esimeseks eesmärgiks oli analüüsida FQSAR meetodil leitud 
potentsiaalsete HCV NS3/4A proteaasi inhibiitorite omadusi. FQSAR on mee-
tod, mis võimaldab soovitud omadustega keemiliste ühendite struktuuride gene-
reerimist in silico. Sellisel viisil valiti välja seitse HCV NS3/4A proteaasi inhi-
biitori-kandidaati. Kõik analüüsitud ühendid omasid võimet suruda maha vii-
ruse replikatsiooni kultiveeritavates rakkudes. Paraku võis see efekt enamikel 
juhtudel tuleneda ühendite tsütotoksilistest kõrvalmõjudest. Vaid üks ühend 
(23332) inhibeeris viiruse replikatsiooni kontsentratsioonidel, mis ei omanud 
kahjulikku toimet viiruse peremeesrakkudele. Samuti näitasid saadud tule-
mused, et rakupõhistest katsesüsteemidest saadud andmed vajavad ülekontrolli-
mist kasutades selleks ensümaatilise aktiivsuse inhibeerimise mõõtmist. 
Töö teiseks eesmärgiks oli analüüsida uudsete 8-oxo-G lämmastikaluseid 
sisaldavate antisense oligonukloetiidide (ASO) omadusi ning võimet inhi-
beerida HCV replikatsiooni. ASO sihtmärkjärjestused HCV kodeerivas regioo-
nis valiti välja RNAi-l põhineval meetodil. ASO, mis sisaldasid LNA aluseid 
mõlemas oligonukleotiidi otsas inhibeerisid HCV replikatsiooni. See efekt säilis 
ka 8-oxo-dG modifikatsioonide lisamisel ASO kesksesse ossa. 8-oxo-dG 
modifikatsoon vähendas ASO sulamistemperatuuri, kuid ei mõjutanud RNaas H 
vahendatud sihtmärk RNA lagundamist. Lisaks suurendasid sellised modifikat-
sioonid ASOde stabiilsust bioloogilises keskkonnas. Seega võimaldas LNA 
aluste ja 8-oxo-dG modifikatsioonide kombineerimine saada kõrge HCV-vas-
tase aktiivsusega ühendid. Samas olid saadud inhibiitorid tundlikud punktmutat-
sioonidele ASO sihtmärkjärjestuses ning omasid kõrgematel kontsentrat-
sioonidel tsütotoksilist efekti. Sellest võib järeldada, et 8-oxo-G modifikat-
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sioone sisaldavad ühendid omavad perspektiivi eelkõige rakuliste sihtmärkide 
(nagu kasvajates üle-ekspresseeritavad onkogeenid) mahasurumisel. 
Chikungunya viirus (CHIKV, perekond Alfaviirus) on troopiline arboviirus 
mis on viimasel aastakümnel korduvalt väljunud oma tavalisest levialast ja 
põhjustanud epideemiaid erinevates maailmajagudes. Antud töö kolmandaks 
eesmärgiks oli analüüsida uudsete CHIKV-vastaste vaktsiinikandidaatide 
geneetilist stabiilsust ning uurida nendes sisalduvate viirust nõrgestavate mutat-
sioonide mõju CHIKV elutsüklile. Selleks analüüsiti kahte potentsiaalset 
CHIKV vaktsiinitüve, mis sisaldavad suuri (≥150 alust) deletsioone viiruse 
valke kodeerivates alades. Leiti, et need viirused (CHIKVΔ5nsP3 ja 
CHIKVΔ6K) omavad nõrgestatud fenotüüpi ka peale mitmekordset passeeri-
mist koekultuuri rakkudes. Mitmetest analüüsitud CHIKV-vastastest vaktsiini 
kandidaatidest osutus kõige efektiivsemaks CHIKVΔ5nsP3. Täiendavad ana-
lüüsid näitasid, et regioon, mis on selles vaktsiinikandidaadis eemaldatud, täi-
dab erinevate alfaviiruste infektsioonis erinevaid funktsioone. Erinevalt 
CHIKV’st on see region Semliki Forest viiruse (SFV) puhul vastutavaks raku 
PI3K-Akt-mTOR signaalraja aktiveerimise eest. Lisaks selgus, et nii CHIKV 
kui ka SFV taluvad vastava regiooni eemaldamist kuid mitte selle väljavaheta-
mist teisest viirusest pärineva järjestuse vastu. Selline vahetus vähendas drasti-
liselt viiruste infektsioonilisust ja põhjustas adaptiivsete mutatsioonide tekki-
mist. Selliste mutatsioonide paiknemine viitab sellele, et CHIKV nsP3 C-termi-
naalne regioon interakteerub sama valgu keskmise domeeni ning nsP2 valgu  
C-terminaalse osaga ja et need interaktsioonid on olulised viiruse replikaasi 
moodustamisel. Need avastused võimaldavad edaspidi välja selgitada 
CHIKVΔ5nsP3 mitte-patogeense fenotüübi põhjused. 
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